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Growth inhibitory proteins limit axonal regeneration in the injured spinal cord and a 
common effector of many of these inhibitors is the Rho family of small GTPases. 
Activation of RhoA leads to growth cone collapse and neurite retraction. An enzyme 
from Clostridium botulinum, C3 transferase, has recently been shown to block RhoA 
function by ADP ribosylation of the effector domain, and this promotes regeneration of 
injured neurons. Current methods for the delivery of C3 are inefficient and suffer from 
various drawbacks that limit its clinical application. The aim of this work was to develop 
a microsphere-based controlled delivery system for cell-permeable C3 protein that can be 
implanted in the injured spinal cord. The approach of blending capped (hydrocarbon end 
groups) and uncapped (free acid end groups) poly(D,L-lactide-co-glycolide) (PLGA) to 
achieve the desired continuous release of C3 was investigated. A recombinant, chimeric 
C3 protein incorporating a protein transduction domain from Tat, was first purified, and 
its purity, efficacy of cellular uptake and in vivo biochemical activity was demonstrated. 
C3-Tat loaded microspheres were prepared by a w/o/w extraction-evaporation technique. 
The microspheres were prepared from pure uncapped and capped PLGA and blends of 
70/30, 50/50 and 30/70 ratios of capped/uncapped PLGA. Mean diameter of the 
microspheres ranges from 74 to 85 µm, with high encapsulation efficiencies of more than 
80%. In vitro incubation of the microspheres in a HEPES buffer was carried out to assess 
the release profile and degradation behaviour. The degradation rate of the microspheres 
can be controlled by the blending ratio of capped and uncapped PLGA. The release of 
C3-Tat from the microspheres was controlled by matrix erosion, where interconnected 
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channels facilitated diffusion of the protein from the matrix.  It was demonstrated that the 
optimal blending ratio giving rise to microspheres fulfilling the requirement of 
continuous release for at least one month, was a 30/70 ratio of capped/uncapped PLGA.  
In this formulation, an average daily C3-Tat release of 3.0 ng/day/mg microspheres was 
observed for a period of one month. While this study has demonstrated the suitability of 
the release characteristics of the microspheres for our target application, the activity 
levels of released C3-Tat could not be accurately assessed, given the instability of the 
protein in the in vitro release conditions. 70% of the released C3-Tat on the first day of 
incubation was found to be active. At least 40% of C3-Tat biological activity was 
maintained in the 30/70 microspheres for 19 days. Further characterization of the C3-Tat 
microspheres in rodent models of spinal cord injury is necessary for more accurate 
assessment of its biological activity. This study demonstrates the feasibility of 
encapsulation of C3-Tat into PLGA microspheres to provide constant delivery of C3-Tat 
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1.1. Spinal cord injury 
Three phases of injury, acute, secondary and chronic (Table 1), can be identified upon 
trauma to the spinal cord [1, 2]. The extent of these injuries determines the severity of 
motor and sensory function impairment. Traditionally, medical care involves removal of 
bone, disc and ligament fragments to decompress the swollen cord. One of the first 
pharmacological treatments for spinal cord injury is the steroid methylprednisolone, 
which may act by decreasing swelling, inflammation and free radical accumulation. It is 
widely accepted that comprehensive treatment should be a sequence of different 
interventions implemented at different intervals after injury. Current research is focused 
on therapies which reduce tissue damage at the injury site, promote axonal regeneration, 
restore appropriate myelination to damaged and regenerating fibers and achieving 










Table 1: Pathophysiology of spinal cord injury. 
Stages of injury Features 
Acute 
 (from moment of 
injury to the first few 
days after injury) 
• The initial mechanical damage of neural and other soft tissue, 
e.g. endothelial cells of vasculature resulting from the trauma, 
leading to cell death 
• Propagation of action potentials along axons is slowed or 
completely blocked (electrolytic shifts), leading to failure in 
normal neural function and spinal shock 
• Hemorrhage, localized edema, vasospasm 





(minutes to weeks 
after injury) 
• Excitotoxicity occurs whereby glutamate floods out of axon 
tips due to cell lysis from mechanical injury.  This overexcites 
neighbouring neurons, which in turn let in waves of calcium 
ions that trigger production of free radicals, killing otherwise 
undamaged neurons. 
• Excitotoxicity also affect oligodendrocytes (CNS myelin 
producing cells) which explains why unsevered axons become 
de-myelinated and therefore cannot conduct impulses 
• Apoptosis (cell suicide) of oligodendrocytes and neurons 
• Neutrophils and lymphocytes invade the spinal parenchyma 





(days to years after 
injury) 
• Ion channel expression levels and activation states are altered 
• Cyst forms, and continues to enlarge in a condition called 
syringomyelia 
• Severed axons exhibit regeneration and sprouting but grow no 
longer than 1 mm 
• Neural circuits altered due to change in inhibitory and 
excitatory impulses 









1.1.1. Axonal regeneration in the injured spinal cord 
At the injury site, neurons die by necrosis, apoptosis or a combination of both. Any 
surviving neurons may be temporarily incapacitated by metabolic and ionic changes in 
their environment. Axons which are severed immediately upon injury undergo little 
spontaneous regeneration. Wallerian degeneration occurs distal to an injury, and in some 
cases the axotomised neuron dies due to loss of target derived, retrogradely transported 
trophic factors. The regenerative failure of mature central nervous system (CNS) axons 
after injury is one of the major reasons for little functional recovery in patients.   
 
It is now clear that adult CNS axons are not intrinsically incapable of regeneration. To 
understand this, mechanisms of axonal growth during embryonic development should 
first be considered. As the nervous system develops, newborn neurons extend axons and 
dendrites toward their appropriate targets. The task of locating the target falls on the 
growth cone, the motile tip of a growing axon or dendrite. The growing axon grows on a 
strongly permissive substrate containing growth promoting molecules such as laminin. In 
addition, specific patterns of distribution of attractive and repulsive guidance cues guide 
axons to their targets. In the early postnatal period after all the major CNS tracts are laid 
down, the mammalian CNS loses the ability both to regenerate axons and to reestablish 
functional synaptic contacts. Reasons for this include absence of growth promoting 
substrate molecules and neurotrophic factors which mediate cell survival and neurite 
outgrowth during development. In addition, resting concentrations of cAMP are lower, 
which makes the growth cone more sensitive to several growth inhibitory molecules. 
Hence the growth permissive CNS environment changes to a nonpermissive one in the 
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adult. This change may only partially occur in the peripheral nerves, since axons 
regenerate in adult peripheral nervous system after injury.   
 
Strong correlation between the failure of CNS axon regeneration and the deposition of a 
glial scar at the injury site shows that one of the main barriers to regeneration after injury 
is the presence of axonal growth inhibitors in the glial scar including proteoglycans, 
tenascins, ephrins and semaphorin III [3, 4, 5]. Experiments [6] have also shown that 
axons failed to extend over oligodendrocytes and CNS myelin in culture. Several CNS 
myelin/oligodendrocyte derived axon growth inhibitory ligands have since been isolated, 
which includes nogo, myelin-associated glycoprotein (MAG) and oligodendrocyte-
myelin glycoprotein (OMgp) [7, 8, 9].    
 
 
1.1.2. Signal transduction in axonal regeneration 
Binding of inhibitor molecules to their transmembrane receptors on growth cones 
regulate axon pathfinding in the developing embryo. In adult, similar inhibitory 
interactions probably mediate plasticity and stabilize established connections [10]. After 
CNS injury, inhibitory ligand expression is upregulated and interaction with their 
receptors located on axon growth cones cause growth cone collapse and account for 
failure of damaged axons to regenerate.   
 
Axonal growth cones rely on actin rearrangements and microtubule assembly to drive 
growth and guidance. The Rho family of small GTPases regulates the actin cytoskeleton 
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in both neuronal and non-neuronal cells. The most widely expressed small GTPases of 
the Rho family are RhoA, Cdc42 and Rac1. Rho GTPases act as molecular switches to 
control signal transduction pathways that link membrane receptors to the cytoskeleton.  
They cycle between active (GTP-bound) and inactive (GDP-bound) states through the 
binding of guanine nucleotides. The cycling of Rho GTPases is regulated by either 
enzymes that enhance GTP-binding activity (guanine nucleotide exchange factors, GEF) 
or proteins that increase GTP hydrolysis (GTPase activating proteins, GAP). When GTP 
bound, Rho GTPases can interact with a series of intracellular effectors to reorganize the 
cytoskeleton in two ways, first, by regulating actin filament assembly and disassembly by 
controlling actin polymerization, branching, and depolymerisation and second, by 
directing actin-myosin dependent contractility to control the retrograde transport of f-
actin within the growth cone. In neuronal cell lines, activation of RhoA stimulates 
actinomyosin contractility and stress fiber formation, resulting in growth cone collapse. 
The activation of Cdc42 and Rac1 leads to extension of filopodia and lamellipodia, 
respectively.  
 
Recent studies have shown that GTPases in neurons are critical signaling mediators 
which link signaling pathways stimulated by myelin associated inhibitors-cell surface 
receptor interaction to the modulation of cytoskeletal dynamics in growth cones [11,12].  
In vitro studies have demonstrated that inactivation of RhoA specifically, by application 
of a bacterial enzyme known as C3 transferase (C3), stimulates primary neurons to 
extend neurites on various growth inhibitory substrates including myelin, chondroitin 
sulphate proteoglycans (CSPG), MAG and Nogo [13, 14, 15]. This points to the 
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requirement of RhoA activation to produce the inhibitory activity of myelin-associated 
inhibitors. In vivo, the regeneration of retinal ganglion cells axons in the optic nerve can 
be stimulated by C3 application [13].   
 
Another recent in vivo study has demonstrated the benefits of C3 treatment in spinal cord 
injury [16]. In the study, C3 was applied to the spinal cord of adult mice in which injury 
had been induced by a dorsal over-hemisection. Long distance regeneration of 
corticospinal axons for up to 12 mm from the lesion site was observed in the treated 
animals, in contrast with axonal retraction in buffer-treated control animals. To assess 
functional recovery, hind limb motor function was measured using a BBB locomotor 
rating scale. The C3 treated mice were walking with body weight support within 24 hours 
after spinal cord injury and initiation of treatment. One month after treatment, the mice 
were walking with hind limb-front limb coordination. The authors speculated that the 
early functional recovery within one day is unlikely to be the result of regenerating axons 
making new functional reconnections. It is possible that these rapid effects may be due to 
reduced tissue loss. Supporting this view are recent studies showing that inactivation of 
RhoA with C3 in ischemic CNS tissue inhibited apoptosis related protein activation in 
neurons and reduced cerebral infarct size [17,18]. The improvement of locomotion at the 
later stages was attributed to long distance regeneration of axons.  This study indicates 






1.2. C3 transferase 
C3 transferase (C3) is an exoenzyme secreted by type C and D strains of the anaerobic 
bacterium Clostridium botulinum [19, 20]. C3 is a basic protein (pI ~ 9.13) of about 25 
kDa. C3 specifically modifies RhoA, RhoB and RhoC proteins from the RhoGTPase 
family via a reaction known as ADP-ribosylation (Fig.1). The other Rho GTPase family 
proteins such as Rac1 and Cdc42 are very poor substrates for C3. This covalent 
modification of RhoA results in inhibition of RhoA dependent processes. The 
interference of RhoA function by C3 is likely due to several mechanisms. One of them 
involves the fact that in the resting state, RhoA is kept in inactive form in the cytoplasm 
by forming a complex with guanine dissociation inhibitor (GDI). It is believed that the 
translocation of RhoA from the cytoplasm to the plasma membrane is necessary for its 
activation. Interaction between RhoA and ERM-proteins (ezrin, radixin, moesin) at the 
membrane is suggested to release RhoA from the GDI complex and exposes RhoA to its 
GEF protein. ADP-ribosylated RhoA accumulates in the cytoplasm and the release from 
GDI is blocked. Accordingly, translocation and activation of RhoA will not occur. In 
order to inactivate RhoA signal transduction inside cells, the majority of RhoA must be 
modified.  ADP-ribosylation of RhoA appears to affect a variety of cellular signal 
transduction processes, including control of smooth muscle contraction, cell adhesion, 
cellular proliferation and transcriptional activation. C3 has been found to be a valuable 








Fig. 1: Mechanism of ADP-ribosylation of RhoA by C3 transferase. (1) Glutamine 
residue at position 172 on C3 interacts with asparagine 41 of RhoA to position the 
acceptor amino acid precisely for the reaction. (2) Glutamic acid at position 174 of C3 
interacts with O2’ hydroxyl group of NAD+, to stabilize the oxocarbenium ion transition 
state of NAD+. (3) Amino group of asparagine 41 is a nucleophile which attacks the 
glycosidic bond in NAD+ and cleaves it. (4) C3 catalyses the transfer of the ADP ribose 

































































1.2.1. Cellular uptake of C3 transferase 
C3 transferase lacks the cell surface binding and transport component that is typically 
found for other families of bacterial toxins. Thus C3 is poorly taken up by cells since it 
does not efficiently cross the lipid bilayer of the plasma membrane. This was proposed to 
be the cause of failure of C3 to promote neurite outgrowth after corticospinal tract lesion 
in the adult rat [14]. In culture studies, invasive means including microinjection [19], 
trituration [20] or scrape loading [21] are necessary to allow C3 to penetrate neuronal cell 
bodies and promote neurite outgrowth. Most studies exploited the ability of C3 to enter 
cells by non-specific endocytosis when applied at rather high concentrations (30-150 
µg/ml) and long incubation times (up to 24-48 hours). Various problems have been 
encountered in the use of invasive methods, including cellular damage, cellular toxicity 
and complex manipulation, all of which preclude their routine use in vivo.  
 
One solution is to create a chimeric protein, comprising of fusion of a small transport 
peptide to C3, thus increasing the efficiency of C3 transduction across the cell membrane. 
The proof of concept for the transduction of proteins into cells was first described in 1988 
independently by Green [22] and Frankel [23] with the discovery that the protein 
transduction domain (PTD) from the human immunodeficiency virus (HIV) Tat protein 
can cross cell membranes. The Tat protein is a transcription transactivator produced by 
the human immunodeficiency virus type 1 (HIV-1) at the early phase of infection, which 
plays a critical role in the expression and replication of the viral genome [24]. This 86 
amino acid protein, which can be secreted from the infected cells, has the ability to enter 
uninfected cells and exert its activity upon the responsive genes. PTDs are small regions 
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of protein which have the ability to traverse biological membranes efficiently through a 
process termed protein transduction. Protein transduction occurs in a rapid, 
concentration-dependent fashion that appears to be independent of receptors and 
transporters but targets the lipid bilayer component of the cell membrane [25]. The ability 
of the Tat PTD to act as a carrier for heterologous proteins across cell membranes has 
been demonstrated through the intraperitoneal injection of a β-galactosidase protein fused 
to the Tat PTD [26]. This resulted in delivery of biologically active fusion protein to all 
tissues in mice.  The membrane-permeating capability of Tat PTD in a receptorless 
fashion renders it a universal transduction system.  
 
The commonly used PTD from Tat protein is the 11-amino acid peptide (Tyr-Gly-Arg-
Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg). A fusion protein of Tat PTD and C3 has been 
reported to efficiently transduce across the plasma membrane of neurons to ADP-
ribosylate and inactivate RhoA intracellularly [27].  The Tat-C3 fusion protein in that 
study also promoted significant neurite outgrowth on myelin substrates. It is clear that the 
fusion of Tat to C3 does not affect the biological activity of C3 in vivo, and is very 









1.3. Protein drug delivery 
Modern biotechnology permits the large-scale production of highly purified proteins to 
be used as drugs in humans. In contrast to low molecular weight drugs, protein 
biopharmaceuticals are generally characterized by high clearances and short plasma half-
lives as a result of rapid degradation by extracellular peptidases or significant receptor-
mediated clearance, and poor passage through biological barriers due to their poor 
diffusivity and low partition coefficient. In addition, protein drugs often possess 
biological activity at multiple tissue sites throughout the body; therefore, systemic 
administration can lead to toxicity. Some of the problems that lead to low efficacy and 
unacceptable toxicity for many protein drugs may be overcome by matching a route of 
administration with an appropriate formulation, with the objective of obtaining an 
appropriate extent and time course of drug action while administering the drug as close as 
possible to its intended site of action.   
 
 
1.3.1. Drug delivery to the spinal cord 
Most of the molecules found to be beneficial to spinal cord regeneration, such as 
neurotrophic factors, and more recently, C3 transferase, are large proteins. In addition to 
the physicochemical properties of protein drugs described previously, the anatomy of the 
spinal cord poses a unique challenge for localized administration of such drugs to the site 
of injury in the spinal cord in biologically relevant amounts and for prolonged periods of 
time. Anatomical features of the spinal cord which have implications in spinal cord drug  
delivery will be discussed in the next section. 
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1.3.2. Anatomical features of the spinal cord 
The spinal cord is part of the CNS and in humans, it is a 40 to 45 cm long cylinder of 
nervous tissue of approximately the same thickness as a little finger, extending from the 
lower end of the brain stem to the lower back. The consistency of the cord is soft and 
jellylike. It is protected by the vertebral column, which consists of 33 vertebrae. A 
circular space within each vertebra forms the spinal canal. The nerves linking the spinal 
cord and the periphery, which are responsible for sensory and motor innervation of the 
body other than the head and neck, are called spinal nerves. The spinal nerves exit the 
vertebral canal by way of spaces between adjacent vertebrae, known as intervertebral 
foramina.   
 
The spinal cord is covered by three membranes, known as meninges. The outermost 
layer is the dura mater, a tough fibrous sheath closely applied to the inner layer of bone 
surrounding the spinal canal. Between the dura and the bone is the epidural space, which 
normally contains a small amount of fat and vertebral veins. Beneath the dura mater is a 
thin and delicate membrane called the arachnoid mater. Beneath the arachnoid mater and 
in contact with the spinal cord is the pia mater. The pia mater is a highly vascularized 
membrane providing blood to the spinal cord. The space between the arachnoid mater 
and pia mater is the subarachnoid space. It is filled with cerebrospinal fluid (CSF), 
which surrounds the entire brain and spinal cord. The subarachnoid space is continuous 
around the CNS (brain and spinal cord), hence substances released into the space at one 




CSF is secreted from the choroids plexus, a vascular part in the ventricles of the brain. 
CSF bathes and circulates among these tissues and acts as a shock absorber to protect 
against injury. CSF is low in cells and proteins, but generally similar to plasma in its 
ionic composition. Water and soluble substances are freely exchangeable between the 
CSF and the interstitial fluid of the nervous tissue. The epithelium of the choroid plexus 
represents a barrier between the blood and the CSF, known as the blood-CSF barrier.  
Many substances that can leave the capillaries of the choroids plexus cannot enter the 
CSF. This is important because neurons are extremely sensitive to changes in the 
composition of their environment. The rate of formation of new cerebrospinal fluid (an 
average of about 350 µl/minute in man) is relatively constant and little affected by 
blood pressure or intraventricular pressure. This means that the total volume of CSF is 
renewed more than three times per day. Most of this fluid is returned to the venous 
system through small arachnoid villi that are found in the ducal sleeves accompanying 
spinal nerve roots. 
 
The blood brain barrier (BBB) exists in the brain and spinal cord, separating them from 
the circulating blood, and serves two main purposes: (a) to control the composition of the 
brain interstitial fluid and CSF within extremely fine limits, to maintain neural function, 
and (b) to protect the brain from toxins. The non-fenestrated endothelial cells that form 
the walls of blood capillaries in the brain and spinal cord, as well as their minimal 
pinocytotic activity, both contribute to the properties of the BBB. The significance of the 
BBB to drug delivery is that as a rule, only lipid-soluble small molecule drugs 
administered systemically can cross the BBB into the brain or spinal cord parenchyma.   
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1.3.3. Methods of protein drug delivery to the spinal cord  
Methods of administration effective for low molecular weight drugs, i.e. oral and 
systemic administration cannot be used for protein drugs. Oral administration is not 
suitable because proteins are susceptible to degradation in the gastrointestinal tract.  
Parenteral systemic administration (intravenous, subcutaneous and intramuscular routes) 
is not expected to result in significant concentrations of protein drugs in the spinal cord 
tissue due to the existence of the blood-brain and blood-CSF barriers. These limitations 
necessitate the development of alternative methods for delivery of protein drugs to the 
spinal cord. These methods bypass the blood-brain and blood-CSF barriers and include: 
(a) direct delivery of the proteins either to the CSF or intraparenchymally, and (b) 
implantation of cells genetically engineered to secrete the therapeutic protein [28]. The 
former is of particular relevance to this work and will be discussed in further detail in 
sections 1.3.3.1 and 1.3.3.2. 
 
 
1.3.3.1. Intrathecal infusion 
Delivery of protein drugs to injured neurons via the CSF can be achieved by intrathecal 
injection/infusion into the CSF in the subarachnoid space either at the level of 
medulla/cervical spinal cord (intracisternal) or lumbosacral spinal cord (intralumbar).  
Proteins administered into the subarachnoid space CSF enter the spinal cord parenchyma 
(tissue) by diffusing through the pia mater and will be limited by the circulation and 
clearance of CSF, which occurs rapidly compared with the time required for appreciable 
diffusion into the surrounding tissue. Intrathecal infusion pumps are currently used 
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clinically to deliver analgesics for chronic pain and antispasticity drugs for severe 
spasticity [29]. Continuous intrathecal delivery of potential therapeutic molecules has 
been widely used in animal spinal cord injury models to characterize the response of 
injured neurons to the molecules [30, 31]. Although intrathecal delivery allows long term 
administration of agents, easy termination of treatment and highly controllable dosages, 
there are some serious limitations which pose considerable restrictions for practical 
clinical use. Catheterization of the subarachnoid space is an invasive technique, which 
may require a hemilaminectomy for exposure of the vertebral interspace. Also, 
implantation of the catheter can cause adverse reactions, such as chronic inflammation 
and dural fibrosis, or result in spinal compression or infection, as has been shown in 
rodents and dogs [32]. A second intervention is also required to remove the catheter and 
pump. The distribution of the infusate in the subarachnoid space is not localized, and the 
agents may be redistributed to the systemic and cranial circulation without reaching the 
intended target. This is shown by the discovery that continuous intrathecal infusion of 
ciliary neurotrophic factor in humans led to side effects including development of pain 
syndromes [33].  
 
Although encouraging results have been attained in SCI animal models, intrathecal drug 
delivery techniques still have significant limitations. An optimal drug delivery system 
should provide delivery of the desired agent at the site of injury to prevent systemic side 





1.3.3.2. Intraparenchymal delivery 
In animal models for spinal cord injury, localized delivery of protein drugs have been 
achieved by [28]: (a) intraparenchymal infusion using cannulas connected to osmotic 
minipumps, and (b) entrapment of the drug within slow release materials such as 
gelfoam, fibrin glue, polymerized collagen, and biodegradable polymer microspheres or 
nanospheres and subsequent implantation at the site of injury. Such localized delivery 
methods minimize the risk of inducing side effects on neural systems that are not the 
target of the treatment. 
 
Efficacy of intraparenchymal delivery has been demonstrated in rat models, where 
infusion of nerve growth factor (NGF) into the spinal cord parenchyma was found to 
induce ingrowth of sensory fibers [28]. Intraparenchymal delivery using an osmotic 
minipump offers the same advantages as intrathecal delivery. However limitations 
include the requirement of a chronically implanted cannula, which means multiple 
surgical interventions are necessary. Insertion of a cannula can also cause tissue damage 
and prolonged use of cannulas can result in tissue reaction around the cannula, leading to 
clogging of the cannula, which then prevents continuous protein delivery.   
 
In the second method where the drug is entrapped in slow release polymers, the drug 
gradually diffuses out once the polymer is implanted, or is released as the polymer 
naturally degrades, hence providing supply of the drug for a prolonged period of time. 
Gelfoam, collagen and fibrin matrices have been shown to be beneficial in spinal cord 
regeneration, as they can serve as physical bridges across the lesion site for neurite 
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extension [34].  However, such matrices have the disadvantage that the rate of delivery 
cannot be controlled and the administered drug may be rapidly depleted due to rapid 
diffusion out of the matrix. An alternative method is to encapsulate the drug in 
biodegradable polymeric microspheres, which can then be administered by injection 
directly into the spinal cord parenchyma. By carefully choosing the polymer and its 
configuration it is possible to predetermine the rate of release for the particular drug.   
 
 
1.3.4. Delivery of C3 transferase to the spinal cord 
For successful treatment of spinal cord injury with C3, two major requirements must be 
met. First, as C3 displays non-specific activity in non-neural tissues, it must be delivered 
directly into the injured site of the spinal cord. Investigations of the temporal changes in 
expression of inhibitory molecules at the lesion site indicates prolonged persistence of 
these proteins in degenerating fibre tracts, which may contribute to the maintenance of an 
environment that is hostile to axonal regeneration. In mature mammals, CSPGs are 
secreted rapidly within 24 hours after injury and can persist for many months [35].  
Myelin associated proteins including Nogo were detected in post-mortem spinal cords of 
patients even three years after injury [36]. Therefore, the second requirement for C3 
treatment is that administration of C3 should be sustained for an extended period of time.   
 
Two methods of continuous delivery which have been tested in mouse models of spinal 
cord injury are continuous intrathecal infusion of C3 solutions using an osmotic 
minipump [14] and release from collagen gels and fibrin soaked with C3 solutions [16]. 
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They both have major limitations which can affect clinical efficacy of C3 treatment. The 
risks of intrathecal delivery in clinical applications are high due to the possible non-
specific effect on neuronal systems that are not the target of the treatment.  In the gel 
delivery method, C3 was first added to a solution of either fibrinogen or collagen and 
applied to the lesion site. Polymerization of the solution occurred after application to the 
lesion, forming a gel entrapping C3. This formed a reservoir of C3 immediately available 
to the injured neurons. Although the use of collagen and fibrin matrices in SCI is 
beneficial as they support tissue repair, there are significant limitations preventing their 
practical use. Studies using simple admixtures of other protein drugs with fibrin have 
demonstrated a large uncontrolled burst release of 70-100% of the drug within the first 24 
hours [37, 38]. Sustained release of therapeutic molecules from collagen matrices is also 
beset with difficulties as fibrillar collagen gels have an effective pore size of several tens 
of nanometers, too large to control release by hindered diffusion [39]. As with fibrin 
matrices, collagen matrices have poor loading capacity for protein molecules. Hence 
without further modifications, for example by creating affinity sites on the gel to bind C3, 
or by chemically coupling C3 molecules to the gel matrix, the matrices would be rapidly 
depleted of the C3 protein, and this clearly limits their use for long term regeneration 
therapy.   
 
To harness the promising therapeutic potential of C3 in spinal cord injuries, 
microencapsulation of C3 in poly(D,L-lactide-co-glycolide) (PLGA) microspheres is 
proposed as an alternative approach for sustained release. PLGA is biocompatible to 
spinal cord tissue and degrades to toxicologically acceptable products that are eventually 
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eliminated from the body [40]. C3 is gradually released as the microspheres degrade and 
erode. The rate at which release occurs can be controlled by the properties of the PLGA 
used. Microencapsulation of C3 will be advantageous as neurons will not be exposed to 
the entire dose of the protein at one time, but instead, will receive a constant and 
consistent daily dose over a prolonged period of time.   
 
 
1.4. Microencapsulation of protein drugs 
Entrapment of protein drugs within microparticulate drug delivery systems, using various 
types of biodegradable polymers, has been studied during the past two decades. Such 
controlled-release devices can be engineered to provide precisely controlled, prolonged 
protein drug delivery at a localized site. An additional advantage of using biodegradable 
polymers is that such additional surgery is not required to remove the devices. At the time 
of writing, there has been no commercial microencapsulated protein drug meant for 
treatment of spinal cord injury. However, clinical efficacy of microencapsulated drugs 
have been demonstrated in other applications and these include recombinant human 
growth hormone (Nutropin Depot®, Genentech-Alkermes) and leuprolide acetate (Lupron 
Depot®, Takeda-Abbott) [41, 42]. 
 
One of the most common methods of preparing microspheres involves emulsification and 
subsequent organic solvent evaporation [43]. Two techniques of emulsification are 
normally used: the water-in-oil-in-water (w/o/w) or the solid-in-oil-in-water (s/o/w) 





   
 
  





Fig. 2: Encapsulation of a protein into microspheres following a typical w/o/w 
emulsification technique. (1) Primary emulsification: aqueous solution of protein is 
emulsified into a polymer solution, (2) Re-emulsification: primary emulsion (w/o) is 
further emulsified into a second aqueous phase containing a stabilizer PVA to form 
w/o/w double emulsion, (3) Solidification: the organic solvent is extracted in the 
continuous aqueous phase resulting in precipitation of polymeric microparticles, (4) 
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Most protein microencapsulation studies have used poly(lactic acid) (PLA) or PLGA.  
PLGA and PLA are the most investigated and advanced polymers with regard to 
available toxicological and clinical data [40]. These polymers are non-toxic, 
biocompatible and biodegradable and approved by the Food and Drug Administration for 
human use. PLGAs (Fig. 3) undergo in vivo and in vitro degradation in an aqueous 
environment by means of hydrolytic cleavage of their backbone ester linkages. The 
degradation products are lactic and glycolic acid which are easily eliminated from the 
body. Hydrolysis of ester bonds can be catalysed by free carboxyl end groups within the 
same molecule (intramolecular catalysis) or by other acidic moieties such as lactic and 
glycolic acids, products of PLGA degradation that accumulate within the hydrated 
microsphere (intermolecular catalysis) [40].  
 
 
Fig. 3: Chemical structure of PLGA (x = lactic acid monomer, y = glycolic acid 
monomer). 
 
Work on encapsulation of low molecular weight drugs and peptides in microspheres have 
been well established. However, delivery of large proteins using microspheres is much 
more challenging because of several reasons. The larger size and complex, well defined 
tertiary/quaternary structure has bearing on release behavior and stability during the 
encapsulation process and release from microspheres. Two critical issues must be 
addressed in order to ensure continuous delivery of biologically active protein from 
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PLGA microspheres for an extended period of time: the control of the protein release 
kinetic profile and the retention of biological activity after release. It is important to 
obtain continuous cumulative release of over 90% of encapsulated protein during the 
treatment period with a concomitant retention of sufficient biological activity [44].   
 
 
1.4.1. Protein release characteristics 
For low molecular weight drugs, release from microspheres occurs by classical partition-
dependent diffusion [45]. The large size of proteins and their insolubility in polymers 
means that such diffusional transport through the polymer phase is minimal. Hence 
release of protein from PLGA microspheres is largely dependent on diffusion through 
existing water-filled pores or on polymer degradation and subsequent polymer erosion.   
 
The dependence of protein release on polymer degradation can be understood if the 
degradation and erosion process in an aqueous environment is first considered. Four 
stages in the in vitro degradation of PLGA can be distinguished and these are indicative 
of the bulk erosion process [46] (Fig. 4): 
(a) an initial lag period during which hydration of the polymer occurs 
(b) random ester bond cleavage throughout the polymer matrix, resulting in a decrease in 
molecular weight (but no microsphere erosion yet) 
(c) continued bond cleavage to a critical molecular weight resulting in onset of polymer 
mass loss (i.e. onset of microsphere erosion), caused by solubilization of the low 
molecular weight polymer fractions 
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(d) complete solubilization (i.e. complete microsphere erosion) 
 
Fig. 4:  In vitro degradation of PLGA immersed in aqueous solution. 
 
Generally, depending on the type of PLGA used, release of encapsulated proteins from 
microspheres immersed in an aqueous environment occurs in three phases that follow the 
stages of degradation of the polymer [47]. Within 24-48 hours after hydration, protein 
located at or near the surface of microspheres dissolves and diffuses out into the medium. 
This first phase is commonly known as the initial burst.  This phase is followed by a 
diffusional release phase during the period before erosion of the polymer matrix begins. 
The diffusional release occurs through water-filled networks of pores and channels, hence 
is dependent on the rate of water uptake into the microspheres and the level of existing 
porosity within the matrix. In the third phase, erosion of the polymer occurs resulting in 
pore formation and fragmentation of the microspheres thus enhancing drug release. This 
phase is also sometimes known as the ‘second burst’. The second burst has been shown to 
coincide with the onset of mass loss of the polymer matrix. The penetration of water is a 
critical factor in the chain of events leading to the depletion of drug from a degradable 
depot because both drug diffusion and polymer matrix erosion are driven by water 

















The degradation rate of PLGA microspheres is dependent upon such factors as the 
polymer physicochemical properties (e.g., molecular weight, lactide/glycolide ratio, 
endgroup chemistry, crystallinity), microsphere properties (e.g., size, surface 
morphology, porosity) and environmental factors (e.g., aqueous medium, pH, 
temperature), all of which affect accessibility of the ester linkage to water [44, 48, 49]. 
These properties of PLGA microspheres determine the degree of hydrophilicity of the 
matrix, and therefore rate of water uptake into the matrix, degradation kinetics and rate of 
protein release. PLGA polymers with physicochemical properties such as lower 
molecular weight, lower lactide/glycolide ratio and free carboxylic endgroups have been 
shown to exhibit a higher degree of hydrophilicity and therefore, hydrolytic cleavage of 
polymer chains begins earlier and at a higher rate [48]. Microsphere properties such as 
surface morphology, internal porosity and size can be controlled by the production 
parameters in the double emulsion process. For example, the final internal porosity is 
controlled by both the volume ratio of internal aqueous solution to the organic phase and 
the method of emulsification of the primary emulsion [50].  
 
Depending on the degradation kinetics of the polymer, two main types of release profiles 
have been reported for protein drugs. A biphasic or parabolic profile [51] arises if protein 
diffusion is significant during the diffusional phase of release so that a continuous release 
is seen up to the point when polymer erosion begins. A triphasic or S-shaped profile [52, 
53, 54] is obtained if protein diffusion is minimal during diffusional phase, giving rise to 
a lag period. At the onset of matrix mass loss, the release of protein increases 
dramatically, giving rise to a second burst.   
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1.4.2. Methods to modulate release characteristics 
As was discussed in the previous section, the rate of water uptake by the microsphere 
matrix determines the rate of degradation of the polymer, and this in turn affects the rate 
of release of the entrapped protein drug. Customization of release characteristics for a 
particular application is important to ensure clinical efficacy. In this respect, the 
knowledge that the rate and extent of water ingress by the microsphere matrix is 
dependent on microsphere microstructure and polymer physicochemical properties has 
been used to develop methods for controlling drug release characteristics. In some cases 
where the use of entirely new polymers is not of interest, approaches which exploit the 
properties of existing polymers can be used.   
 
One of the approaches is to manipulate the porosity of microspheres, such that the release 
of protein is primarily via diffusion through interconnected pores or channels in the 
microspheres. In this way, protein diffusion is significant after the initial burst, hence 
eliminating the lag period. To achieve this, studies which involve the incorporation of 
poly(ethylene glycol) (PEG) into a poly(D,L-lactide) matrix have been carried out [55].  
The addition of the hydrophilic PEG led to increased water uptake and its dissolution in 
the release medium creates more water channels, thereby allowing diffusion of the acidic 
degradation products out of the polymer. This gives rise to a release profile that is 
characteristic of diffusion through water-filled pores in the microsphere. A major 
disadvantage of this method is that the water soluble nature of PEG will also lead to 
lower entrapment levels of the protein. In another recent study [56], built-in nano-porous 
and interconnected channels within the microspheres were obtained by judiciously 
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selecting a low molecular weight poly(L-lactide) as the matrix material. Entrapped 
proteins were released completely, in a diffusion-controlled manner. However, a 
drawback of this method is that the slowly degrading PLA microspheres may elicit 
undesirable foreign body reactions when administered into the body. 
 
The second approach to modulating release profile involves fine-tuning the degradation 
rates of the polymer, either by copolymerizing or physical blending of different polymers. 
In this way, polymer erosion begins early in the incubation period to achieve drug release 
even during the initial period, when release is normally governed by dissolution and 
diffusion of solubilised drug from the polymer matrix. Blending of polymers with faster 
degradation rates have been shown to increase the release rates in the period after the 
initial burst [57, 58, 59]. In one study [57], bovine serum albumin (BSA) loaded 
microspheres prepared with 75:25 PLGA alone showed very little degradation in the first 
24 days, resulting in minimal release of BSA. When amorphous D,L-PLA with a low 
molecular weight of 2000 Da was blended with the 75:25 PLGA in a suitable proportion, 
the degradation rate increased and zero-order release kinetics were observed. It was 
found that the incorporation of D,L-PLA into the microspheres led directly to an 
increased rate of water uptake, thereby increasing its degradation and erosion rate, 







1.4.3. Protein stability 
Apart from release characteristics, a very important criterion for microspheres is the 
capacity to deliver the protein drug in a biologically active form. Protein stability can be 
compromised during the various stages of microsphere processing, storage and 
application. Protein instability can be of chemical or physical nature. Physical instability 
develops through conformational changes leading to denaturation, surface adsorption, 
aggregation or precipitation of the protein. Chemical instability can occur as a result of 
chemical reactions such as oxidation and hydrolysis. The causes of protein instability as 
well as the methods used to minimize instability have been extensively reviewed [60, 61].    
 
In this section, two major causes of instability and the approaches used to maintain 
protein integrity are briefly highlighted. First, the sonication step in the commonly used 
water-in-oil-in-water emulsification technique is a major cause of degradation [62]. The 
sonication step is necessary for generating homogenous dispersions but can denature 
proteins through large pressure and temperature gradients and high shear forces [62]. In 
addition, sonication exposes the protein to the denaturing action of organic solvent across 
a large interfacial area. To prevent emulsification-induced denaturation, excipients have 
been added to the inner aqueous phase. Some excipients such as bovine serum albumin 
[63], PEG 3350 [64], PEG 400 [65], gelatin [66] work by accumulation at the 
water/organic solvent interface, thereby shielding the interface from the protein drug.  
During release, a major cause of protein degradation is the acidification of the 
environment as the polymer degrades [67]. This can cause aggregation and denaturation 
of the protein, leading to incomplete release, or release of inactive protein. To inhibit 
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acid-induced protein degradation during release, poorly water soluble basic inorganic 
salts such as magnesium hydroxide [68] have been incorporated into the microspheres.   
 
 
1.5. Motivation and Objectives 
Methods which have been used for the delivery of C3 transferase to the spinal cord injury 
site have so far been inadequate to ensure successful therapy clinically. As such, there is 
a need to develop a delivery system which allows the rate of release to be controlled, 
thereby ensuring a continuous supply of active C3 in therapeutic amounts during the 
entire treatment period. The use of PLGA microspheres as a delivery vehicle for C3 is 
proposed as an alternative approach for sustained release. The rationale for this choice is 
that the rate of release of C3 incorporated within PLGA can be tightly coupled to the 
degradation rate of the matrix, and hence can be controlled by judicious selection of 
polymers. 
 
The objective of this study was to encapsulate C3 transferase within PLGA microspheres 
to produce a sustained release formulation that will deliver active C3 in therapeutic 
amounts in the time period needed for axonal regeneration. As pre-clinical studies of C3 
are still in the initial stages, clinically relevant amounts of C3 and the period of release 
have not yet been established. Previous studies in animal spinal cord injury models 
indicate that continuous supply of C3 for a period of one month may be necessary for C3 
to show its positive therapeutic effects [16]. In addition, due to the high potency of C3, 
daily supply of nanogram levels of C3 may be sufficient.   
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In particular, two major issues were addressed in this study. First, the poor cellular uptake 
of native C3 necessitates the addition of a protein transduction domain to C3 to ensure 
efficient uptake. In this respect, a domain derived from the Tat protein of the human 
immunodeficiency virus was used as it has been shown to improve cellular uptake 
significantly and does not affect C3 activity. By increasing the efficiency of C3 entry into 
cells, lower concentrations of C3 can be used, hence minimizing toxicity issues. The 
second issue is the control of the protein release characteristics. In this study, the efficacy 
of blending two PLGA polymers with different physicochemical properties as a method 
of modulating release characteristics was investigated.   
 
In order to evaluate the feasibility of using C3 microspheres to promote the long term 
regeneration of injured neurons, an in vitro study assessing the microsphere degradation 
characteristics as well as C3 release characteristics and activity of released C3 was 





















2.1.1. Solutions and reagents for purification of C3 transferase 
RIPA lysis buffer: 50 mM Tris.Cl, 150 mM NaCl, 1% NP40, 1 mM Na4P2O7, 1 mM NaF, 
1 mM EDTA, 2 mM Na3VO4, 1x protease inhibitor cocktail (Roche). 
 
10× thrombin cleavage buffer: 500 mM Tris.Cl pH 8.0, 1.5 M NaCl, 25 mM CaCl2, 20 
mM MgCl2, 10 mM dithiothreitol. 
 
Sample buffer for SDS-PAGE: 125 mM Tris.Cl pH6.8, 25% glycerol, 2% SDS, 5% β-
mercaptoethanol, bromophenol blue. 
 
Coomassie Blue staining solution: 2 tablets of R250 Coomassie blue (R250, Merck), 50 
ml methanol, 12.5 ml acetic acid, 75 ml ddH2O. 
 
Coomassie Blue destaining solution: 20 ml acetic acid, 60 ml methanol, 120 ml ddH2O. 
 




2.1.2. Materials for microsphere preparation  
Two types of PLGA 50:50 polymers, with different polymer end groups, were used to 
investigate the effects of blends of different ratios of the two polymers on the release 
profile. The polymer endgroup is determined by the choice of initiator used in the 
polymerisation reaction. Uncapped PLGA contains free carboxyl end groups at the 
polymer terminus, which cause increased hydrophilicity, faster and larger extent of water 
uptake and hence faster degradation in aqueous environments [69]. Capped PLGA 
contains hydrophobic lauryl ester groups at the polymer terminus which give a 
hydrophobic property to the polymer. The polymers were purchased from Alkermes and 
their weight-average molecular weights as determined by gel permeation chromatography 
were 35000 Da for the capped polymer and 12500 Da for the uncapped polymer.  
Polyethylene glycol (PEG, Mw 3350, Sigma) was included in the C3-Tat solution at a C3: 
PEG mass ratio of 1:4.  PEG has been shown to be effective in stabilizing basic proteins 
during the w/o/w double emulsion process [65]. 
 
 
2.2.   Preparation of cDNA encoding recombinant C3 transferase 
cDNA encoding C3 transferase in the plasmid pGEX2T was kindly provided by Dr. 
Lamarche V.N. (McGill University, Department of Anatomy and Cell Biology, Montreal, 
Canada). The DNA construct was modified by recombinant DNA techniques to add the 
Tat peptide and hemaagglutinin (HA) peptide to the N-terminal of C3 transferase.  The 
amino acid sequences for Tat and HA are YGRKKRQRRR and YPYDVPDYA 
respectively. The full amino acid sequence of C3 transferase can be found under the 
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NCBI accession number CAA35828. 
 
To achieve this, KpnI and EcoRI restriction sites were first added to the 5’and 3’ends of 
C3 transferase by PCR, respectively, using the forward primer C3F2 [5’-
aaggtaccgcttattccattaatcaa-3’] and reverse primer C3R2 [5’-aagaattctctttaggattgatagctgt-
3’] and pGEX2T-C3 as the DNA template. The PCR product was first subcloned into 
pCAP plasmid vector using EcoRV restriction site, and then released with KpnI and 
EcoRI restriction enzymes. The resulting DNA fragment was then subcloned into pHM6 
plasmid vector (which contains the HA tag) using KpnI and EcoRI sites, creating pHM6-
C3. The sequence of this plasmid was first verified by DNA sequencing to be correct, 
before proceeding with the next step. In the next step, the primers Tat-S [5’-
gcatatgtacggtcgtaaaaaacgtcgtcagcgtcgtcgtggt-3’] and Tat-AS [5’-
ctagaccacgacgacgctgacgacgttttttacgaccgtacatatgc-3’] were self-annealed and then 
subcloned into pGEXKG plasmid vector via SmaI and XbaI sites, creating pGEXKG-Tat. 
This plasmid was sequenced to verify that Tat has been incorporated correctly.  
Using another set of primers XbaHAF1 [5’-aatctagaatacccatacgacgtccca-3’] and HM6R1 
[5’-ggcacagtcgaggctgatca-3’], and pHM6-C3 as the template, the HA-C3-His6-Stop 
fragment was PCR amplified to incorporate an XbaI restriction site at the 5’ end. The 
PCR product was digested with XbaI and SacI restriction enzymes and the resulting 
fragment subcloned into pGEXKG-Tat via XbaI and SacI restriction sites. This results in 
the final expression construct, pGEXKG-Tat-HA-C3 which upon expression and 
purification will yield the desired recombinant C3 transferase, with Tat peptide and HA 





As a control in subsequent experiments, an expression construct for C3-HA without the 
Tat peptide attached was also prepared. This protein is designated as unmodified C3.  For 
this, the XbaI and SacI digested HA-C3-His6-Stop fragment prepared earlier was 
subcloned into a pGEXKG plasmid via Xba1 and Sac1 restriction sites. 
 
 
2.3.   Purification of recombinant C3 transferase 
The pGEXKG plasmid is designed for inducible expression of genes as fusions with 
glutathione S-transferase protein (GST) in E. coli bacteria. The pGEXKG-Tat-HA-C3 
construct was transformed into protease deficient BL21 E. coli to purify the desired C3-
Tat protein.  The pGEXKG-HA-C3 construct was also transformed into BL21 to purify 
unmodified C3. A single colony was picked from a fresh transformation plate containing 
50 µg/ml ampicillin and inoculated into 12 ml Luria broth (LB) containing 50 µg/ml 
ampicillin. The cells were grown at 37 °C for 16 hours. The overnight culture was diluted 
1:10 in 100 ml fresh LB containing 50 µg/ml ampicilin, and grown for an additional 1 
hour at 37 °C. Expression of the fusion protein was induced by addition of isopropyl β-D-
thiogalactoside (IPTG) to a final concentration of 0.5 mM, and then the culture was 
incubated for another 3 hours at 37 °C. The cells were pelleted by centrifugation at 8000 
rpm for 5 minutes at 4 °C. The cell pellet was resuspended in 10 ml ice-cold 1x PBS and 
then lysed on ice with a probe sonicator, using 10 × 10 second bursts and 10 second rest 
intervals. Insoluble cell materials were removed by centrifuging the lysate at 13000 rpm 
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for 10 minutes at 4 °C.   
 
The soluble GST fusion proteins were purified from the supernatant by affinity 
chromatography on glutathione sepharose 4B (Amersham Biosciences). The process is 
shown in Fig. 5. A 1 ml bed volume of the beads in a 15 ml Falcon tube was prepared 
according to the manufacturer’s instructions. The cleared cell lysate was added to the 
beads and incubated for 1 hour at 4 °C with gentle agitation on an orbital shaker. The 
suspension was centrifuged at 2000 rpm, 4°C for 5 minutes. The supernatant was 
removed and the beads were washed 3 times with 10 ml 1× PBS. The pGEXKG plasmid 
is designed with a thrombin cleavage site upstream of the multiple cloning site. 
Incubation of the GST fusion protein on beads with thrombin results in release of the 
protein of interest from the GST tag. 10 units of thrombin (Amersham Biosciences) in 1× 
thrombin cleavage buffer at a final volume of 1 ml were added to the beads, and the 
beads were incubated for 9 hours at 4 °C with gentle agitation. The suspension was 
centrifuged at 2000 rpm for 5 minutes and the supernatant transferred to a fresh tube. To 
remove thrombin from the purified C3-Tat, 100 µl of p-aminobenzamidine agarose beads 
(Sigma) was added to the supernatant, and incubated for 30 minutes at 4 °C with gentle 
shaking. Finally, the p-aminobenzamidine agarose beads with the bound thrombin are 
pelleted by centrifugation. Any remaining cleaved C3 associated with the sepharose 





Fig. 5: Schematic representation of the purification process of recombinant C3-Tat. 
 
 
2.4. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
The purity of cleaved C3 from each preparation was determined by Coomassie staining 
of SDS-PAGE gels and confirmed by Western blot. Samples were mixed with sample 
buffer and boiled at 95°C before loading onto a 10% SDS-PAGE gel.   
 
 
2.4.1. Coomassie blue staining 
Proteins were visualized by incubating the polyacrylamide gel in Coomassie staining 
solution overnight at room temperature with gentle shaking. Destaining was performed 
with destaining solution until the background staining was eliminated and the protein 
bands were clearly visible. The gel was dried by incubating in a gel drying solution for 2 
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2.4.2. Western blot 
Following electrophoresis, protein samples on the gel were transferred onto nitrocellulose 
membrane (Shleicher & Schuell Bioscience) for 1 ½ hours at 100 V using a wet transfer 
apparatus (Biorad). The membranes was incubated in blocking buffer (2% skimmed milk 
powder in 1× PBS) for 1 hour, followed by an appropriate dilution of anti-HA (Santa 
Cruz) primary antibody. The membrane was washed 3 times with 1× PBS, for 10 minutes 
each. This was followed by incubation for 1 hour with an appropriate dilution of the anti-
rabbit secondary antibody conjugated to horseradish peroxidase (Pierce). The membrane 
was washed 3 times as previously described. All incubation steps were performed at 
room temperature with gentle agitation on an orbital shaker. The membranes were 
developed using Supersignal West Pico (Pierce) substrate. 
 
 
2.5. Protein quantification 
Prior to microencapsulation, the purified C3-Tat solutions from different preparations 
were pooled together and the protein concentration determined using microBCA assay 
(Pierce). Purified C3-Tat samples were diluted 15-fold in ddH2O for the assay. Bovine 
serum albumin (BSA) (Sigma A7906) was used as standards and stock BSA solutions in 
1×PBS were used to perform serial dilutions from 200 to 0.5 µg/ml. The linear range for 
this assay is between 2 – 40 µg/ml. Assay procedures were as described in the 
manufacturer’s manual. Absorbance was measured at 562 nm using a plate reader (Tecan 
Spectra Rainbow Thermo). The standard curve was used to determine the relative protein 
concentration of each sample. 
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2.6. Determination of C3-Tat cellular uptake efficiency 
The efficiency of uptake of the purified C3-Tat into cells was determined by 
immunostaining experiments. NIH3T3 fibroblast cells were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS) and 1% 
penicillin-streptomycin (P/S) in a T75 culture flask. 2.7×104 cells were plated on 12 mm 
circular glass coverslips in a 24-well culture plate and left at 37 °C for 4 hours to allow 
them to settle. After the cells have adhered to the coverslips, the medium was removed 
and replaced with fresh DMEM, with 10% FBS and 1% P/S, together with 10 µg/ml of 
purified C3-Tat or unmodified C3. The cells were incubated at 37°C for 24 hours. The 
medium was removed and the cells were washed three times with 1×PBS. The cells were 
then fixed in 4% paraformaldehyde for 10 minutes, and then washed three times with 
1×PBS. The cells were permeabilised with 0.2% TritonX-100 for 5 minutes, and then 
washed three times with 1×PBS. Next, the cells were blocked with 3% BSA in 1×PBS for 
1 hour. The cells were then probed with anti-HA antibody (Santa Cruz) diluted to 1:100 
in 3% BSA. After 1 hour, the antibody solution was discarded and the cells were washed 
three times with 0.1%BSA in 1×PBS. Next the cells were probed with secondary 
antibody (α-rabbit Alexa Fluor 488, Molecular Probes) at 1:1000 dilution in 3% BSA.  
After 1 hour incubation in darkness, the cells were washed with 0.1% BSA. An 
antifading solution (FluorSave, Calbiochem) was used to mount the coverslips on glass 






2.7. Determination of in vivo biochemical activity of C3-Tat  
The ADP-ribosylation of RhoA by C3-Tat can be detected as an upshift in molecular 
weight of intracellular RhoA on a Western blot. The intracellular activity of purified C3-
Tat was determined by western blot analysis of cells treated with the enzyme. Briefly, 
NIH3T3 cells were plated in a 6-well culture plate at a density of 3.5×105 cells/well. The 
cells were incubated at 37°C for 4 hours to allow them to settle. The medium was 
removed and replaced with complete medium containing either 5 µg/ml or 10 µg/ml C3-
Tat. Complete medium alone was added to one well to serve as treatment control. The 
cells were incubated at 37°C for 24 hours. To harvest the cells, they were washed 3 times 
in 1×PBS, and scraped off the plate with a rubber policeman. The cells were lysed in 
RIPA lysis buffer and then clarified by centrifugation. The amount of protein in the 
cleared lysate was determined using BCA assay (Pierce) and 60 µg of protein was 
separated on a 12% SDS-PAGE gel. The proteins were transferred to nitrocellulose 
membrane as previously described in section 2.4.2. The membrane was probed with anti-
RhoA antibody (Santa Cruz) at a 1:200 dilution, followed by an anti-mouse-HRP 
antibody (Pierce) at a 1:5000 dilution. The membrane was detected with Supersignal 









2.8. Preparation of microspheres 
Microspheres containing C3-Tat were prepared using a water-in-oil-in-water (W/O/W) 
emulsion method adapted from Pean et al [65]. First, a 180 μl aqueous solution of 
purified C3-Tat (100 μg/ml) and PEG (C3:PEG mass ratio of 1:4) was emulsified in 2.34 
ml dichloromethane containing 117 mg PLGA (single or a combination of polymers). 
Emulsification was performed in an ice bath, using a probe-type sonicator (XL2000, 
Misonix) at 3W output for 10 seconds. This water-in-oil emulsion was then added into an 
external aqueous solution of PVA (5% w/v, 35 ml) and stirred at 500 rpm for 1 minute on 
a magnetic stirrer. The resulting water-in-oil-in-water emulsion was added to deionised 
water (300 ml) and magnetically stirred at 500 rpm for a further 30 minutes to extract and 
evaporate the organic solvent. The formed microspheres were washed 3 times with 
deionised water and freeze-dried overnight to obtain a fine white powder. The freeze-
dried microspheres were stored at 4°C until further analysis. Blank microspheres were 
prepared in the same way, but with deionised water as the internal aqueous phase.   
 
 
2.8.1. Polymer blending  
To evaluate the effect of polymer blends on the C3-Tat release profile, C3-Tat 
microspheres were prepared at 100/0, 70/30, 50/50, 30/70 and 0/100 ratios of 
capped/uncapped PLGA.  The samples were named 100/0, 70/30, 50/50, 30/70 and 0/100 





2.9. Determination of morphology and internal microstructure of microspheres 
A scanning electron microscope (SEM) (Model JSM-5600LV, JEOL) was used to 
examine the surface morphology and internal microstructure of blank microspheres 
before and after in vitro degradation studies. Cross-sectioned microspheres were prepared 
by slicing the freeze-dried microspheres with a razor blade. Microspheres and their 
section samples were placed on metal stubs using double sided carbon tape and sputter-
coated with platinum. 
 
 
2.10. Determination of microsphere size  
Diameters of 100 microspheres were determined from representative SEM images using 
the SmileView software and values were expressed as mean ± standard deviation.  
 
 
2.11. Determination of microsphere encapsulation efficiency 
The levels of C3-Tat encapsulated in microspheres were determined using a method 
similar to that reported by Yan et al [70]. A known amount of microspheres (~10 mg) 
was added to 0.9 N sodium hydroxide (150 µl) and shaken on an orbital shaker at room 
temperature for 4 hours. When the microspheres were solubilized completely, the 
resulting clear solution was neutralized to pH 7.0 by a few drops of 0.9 M hydrochloric 
acid. The amount of C3-Tat in the solution was determined by the microBCA assay as 
described in section 2.5. Measurements were performed in triplicate and the results are 
presented as mean ± standard deviation. Encapsulation efficiency was calculated using 
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equation 1, by comparing the amount of protein in the solubilized microspheres as 
detected by the microBCA assay (Wactual) with the amount of protein that should 
theoretically be contained in the same amount of microspheres (Wtheoretical). 
Encapsulation efficiency (%) = Wactual / Wtheoretical × 100                                                  (1) 
 
The microBCA assay is based on the reduction of Cu2+ ions to Cu1+ ions by protein in an 
alkaline medium and the colorimetric detection of the Cu1+ ion using a reagent containing 
bicinchoninic acid (BCA) [71]. While protein is unlikely to be decomposed in 0.9N 
sodium hydroxide, it may be cleaved into smaller peptides. Given the fact that colour 
formation with BCA is strongly influenced by the presence of any of the four amino acid 
residues (cysteine, cystine, tyrosine, tryptophan) in protein as well as by the number of 
peptide bonds, the presence of only a single amino acid residue in the sample still results 
in the formation of a coloured BCA-Cu1+ chelate.  
 
 
2.12. In vitro release studies 
The release profile of C3-Tat from microspheres was determined by incubating 10 mg 
microspheres in 250 µl of a HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid] 
buffer (100 mM HEPES, pH 7.4, 10 mM NaCl) at 37°C with shaking. The studies were 
performed in triplicate. At predetermined time intervals, the microsphere suspension was 
centrifuged at 2000 rpm and the supernatant was collected (250 µl) and replaced with 




2.13. Enzyme-linked immunosorbent assay (ELISA) 
An ELISA assay was developed to quantify the amount of C3-Tat released from the 
microspheres. An indirect ELISA format was used, where the antigen (C3-Tat) is bound 
to the substrate (microplate) and detected with anti-HA primary antibodies and anti-
mouse-HRP secondary antibodies. The optimal primary antibody dilution was first 
determined using a checkerboard titration method with HEPES medium as the coating 
buffer. 
 
To determine the amount of C3-Tat in the release medium samples, 50 µl of the release 
samples was added to the microplate wells (Nunc). The standards used were 50 µl 
purified C3-Tat in HEPES buffer, in a concentration range from 39 to 625 ng/ml. The 
plate was incubated for 20 hours with shaking at 100 rpm at 4 °C. The solutions were 
discarded and blocking buffer (1% BSA in 1×PBS) was added and incubated for 1 hour 
at 100 rpm, at room temperature. The anti-HA antibodies were diluted 1:800 in 1% BSA 
and 50 µl added to each well. Incubation was for 1 hour, 100 rpm, room temperature.  
The wells were washed three times with 1×PBS, and then a 1:5000 dilution of anti-
mouse-HRP antibodies were added. Incubation was for 1 hour, 100 rpm, room 
temperature. The wells were washed three times with 1×PBS, and then ABTS substrate 
(Roche) in acetate buffer was added to each well. After incubation for 30 minutes, the 
absorbance was measured at 405 nm in a microplate reader. A standard curve from 
known quantities of fresh C3-Tat was plotted and amount of C3-Tat in release samples 
were determined from this curve. The value at each time interval was expressed as mean 
± standard deviation. 
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2.14. Determination of change in pH of release medium  
The pH of the release medium at different time points was detected using universal pH 
indicator strips (Merck). 
 
 
2.15. In vitro degradation studies 
Ten milligrams of blank microspheres were suspended in 250 µl of HEPES buffer and 
incubated at 37°C with shaking. For each microsphere formulation, there were three 
replicate tubes for every time point. At one week intervals, for up to 4 weeks, the tubes 
were centrifuged and buffer was removed from every tube. Fresh buffer was added to all 
but one tube. The sample in this tube was freeze-dried for 24 hours. The degraded 
samples were characterized over time by measurement of molecular weights and residual 
mass, and observation of microstructure (by SEM).   
 
Polymer mass remaining was calculated according to equation 2 by comparing the mass 
at a given time point (Wt) to the initial mass (Wo).  Measurements were performed in 
triplicate, and the means were plotted with standard deviation as the error bars. 
 
Percentage mass remaining = (Wt / Wo ) × 100%                                    (2) 
 
Polymer molecular weight was determined by gel permeation chromatography using a   
column on a HP 1100 LC system (Agilent). 1 mg of microspheres was dissolved in 1 ml 
tetrahydrofuran (THF), filtered through a 0.45 µm PTFE filter and 20 µl was injected and 
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eluted with THF at 1 ml/min. Weight-average molecular weights (Mw) were calculated 
with polystyrene standards (Agilent) with molecular weights 580, 7200, 113000 and 
1950000 Da, using the HPChem software. 
 
The degradation rate constant for each microsphere formulation was calculated based on 
the knowledge that the degradation of polyesters such as PLGA proceeds by random 
hydrolytic chain scission of ester linkages, which is autocatalysed by the carboxyl-end 
groups. This process may be described by first order kinetics [72]. The weight average 
molecular weight (Mw) for each sample, at each time point, was first normalized to the 
initial weight average molecular weight (Mwo). Semilog plots of the normalized weight 
average molecular weight versus time (in days) were made. The slope was determined by 
a linear least-squares fit to the data and expressed in units of day-1. The slope represents 
the first-order degradation rate constant of Mw decay. 
 
 
2.16. Determination of enzymatic activity of C3-Tat released into release medium 
Bioactivity of C3-Tat can be assessed by its catalysis of ADP-ribosylation of RhoA, 
which results in an increase in molecular weight of RhoA upon Western blot analysis. A 
modified form of an in vitro ADP-ribosylation assay [73] was used in the present study.  
The cDNA encoding human RhoA in pGEXKG plasmid vector which was kindly 
provided by Denis Gingras (Universite de Montreal) was transformed into BL21 cells for 
expression of RhoA as a GST-fusion protein. The same procedures for GST fusion 
protein purification as described previously for C3-Tat were used. Briefly, a standard 
curve was first set up to obtain a relationship between known amounts of C3-Tat and 
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amounts of ADP-ribosylated RhoA. Known amounts of C3-Tat were obtained by serial 
dilution of freshly purified C3-Tat stock in the same HEPES buffer as that used in the 
release studies, to a final volume of 50 µl. To each tube containing a known amount of 
C3-Tat, 150 µl of a solution containing 400 ng RhoA, 8 µM β-NAD (98% free acid, 
Roche), 5 mM MgCl2 and 1 mM DTT was added. This mixture was incubated at 37°C 
for 2 hours. 10 µl of the reaction mixture was subjected to Western blot detection with 
anti-RhoA antibody (1:500 dilution). The immunoreactivity signal was quantified by 
densitometry using a chemiluminescent imaging system (ChemiGenius2, Syngene, 
Maryland, USA). The extent of ADP-ribosylation was calculated using equation 3 and 
plotted against known amounts of C3-Tat to obtain the standard curve (Fig. 6). 
 
 
Extent of ADP-ribosylation (%) 
 =   densitometric units of ADP-ribosylated RhoA   × 100%    
        densitometric units of input RhoA                       (3) 
 
 
To determine the proportion of C3-Tat that remained active after being released from 
microspheres, 50 µl of medium containing released C3-Tat from each time point was 
incubated with 150 µl of a solution containing 400 ng RhoA, 8 µM β-NAD (98% free 
acid, Roche), 5 mM MgCl2 and 1 mM DTT, for 2 hours at 37°C. Western blot was 
performed with the same conditions as for the standards. The extent of ADP-ribosylation 
was determined as described above, using equation 3. From the standard curve (Fig. 6), 
the corresponding amount of active C3-Tat present in the release sample was determined. 
Comparing this value with the total amount of C3-Tat actually present in the release 
sample (as determined previously by ELISA) gives an indication of the proportion of 
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biologically active C3-Tat in each release sample (equation 4). 
 
Percentage of C3-Tat that remains active after being released (%)  
  = Amount of active C3-Tat in release sample  × 100%            (4)  
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Fig. 6: Standard curve obtained by measuring the extent of ADP-ribosylation for given 
amounts of freshly purified C3-Tat. The standard curve was subsequently used to 
























RESULTS AND DISCUSSION 
 
3.1. Purification of recombinant C3-Tat 
The DNA expression construct (Fig. 7) for C3-Tat was obtained by the addition of Tat 
and HA sequences to the amino terminal of C3 using recombinant DNA techniques.  Tat 
is a protein transduction domain which has been shown to increase cellular uptake of C3, 










Upon expression of this construct in E.coli cells and purification by affinity 
chromatography, the Tat-HA-C3 protein was obtained as a fusion with GST (Fig. 8).  
Subsequent cleavage by thrombin protease at its recognition site situated between GST 
and Tat-HA-C3 produced the purified Tat-HA-C3 protein (thereafter referred to as C3-
Tat). The purity and molecular weight of the GST fusion protein before and after 
cleavage was confirmed by Coomassie staining of SDS-PAGE gel (Fig. 9) and by 
Western blot (Fig. 10). The cleaved C3-Tat protein was later encapsulated in 
microspheres. 
 
               
 
 
Fig. 8: Schematic representation of the GST-Tat-HA-C3 fusion protein purified from 
E.coli cell lysates. 
 
Tat C3 transferaseHA GST




Fig.9:  SDS-PAGE gel stained with Coomassie blue showing protein samples from 
various steps in the GST purification process. The GST-Tat-HA-C3 fusion protein is 
detected as a 56 kDa band in the gel (Eluted GST-Tat-HA-C3 (1) and (2)). 
 
 
Fig. 10: Western blot of purified GST-Tat-HA-C3 and C3-Tat protein (after thrombin 
cleavage) probed with anti-HA and anti-rabbit-HRP antibodies. C3-Tat protein is 
detected as a 28 kDa protein. 
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3.2. Biological efficacy of purified recombinant C3-Tat  
The ability of recombinant C3-Tat and unmodified C3 to enter cells was determined by 
immunocytochemistry (section 3.2.1), while the ability of the proteins to ADP-ribosylate 
RhoA intracellularly was determined by Western blot (section 3.2.2). 
 
 
 3.2.1. Cellular uptake of C3-Tat 
To study the cellular permeability of C3-Tat (containing both the HA epitope and the Tat 
peptide) and unmodified C3 (containing HA epitope but not the Tat peptide), fibroblast 
cells were treated with the purified proteins and immunostained with anti-HA and Alexa 
Fluor 488 antibodies. In Fig. 11, no intracellular staining was observed when cells were 
treated with unmodified C3, but staining was observed when cells were treated with C3-
Tat. This is consistent with the work of other researchers [27], confirming the increased 












      
 
Fig. 11: Efficiency of purified C3-Tat uptake into NIH3T3 fibroblast cells.  NIH3T3 cells 
were incubated with medium containing (a) no added C3, (b) 10 µg/ml unmodified C3, or 
(c) 10 µg/ml C3-Tat for 24 hours and immunostained with an anti-HA antibody, followed 
by anti-rabbit Alexa Fluor 488 antibody. The cells were viewed at 200× magnification.   
 
 
3.2.2. In vivo biochemical activity of C3-Tat 
ADP-ribosylation of RhoA causes RhoA to migrate with a larger apparent molecular 
weight on SDS-PAGE gel [74]. To ensure that the purified C3-Tat has the ability to 
ADP-ribosylate RhoA intracellularly, the electrophoretic mobility of RhoA in fibroblast 
cells treated with the enzyme or with culture medium alone as a control was examined by 





A Western blot of cell lysates with anti-RhoA antibody (Fig. 12) clearly shows an upshift 
in molecular weight of the 22 kDa RhoA upon treatment with 5 µg/ml C3-Tat (lanes 1, 
4).  Untreated control cells (lane 5) showed no apparent ribosylation of RhoA.  
 
 
Fig. 12: Intracellular activity of purified C3-Tat. NIH3T3 cells were incubated in medium 
containing 5 µg/ml C3-Tat (lanes 1 and 4) or 10 µg/ml C3-Tat (lane 2) or no added C3-
Tat (control, lane 5) for 24 hours at 37°C.  It should be noted that for the samples in the 
described lanes, C3-Tat was simply added to the medium without any physical disruption 








3.3. Microencapsulation of C3-Tat in PLGA microspheres 
 
3.3.1. Physical characteristics of PLGA microspheres encapsulating C3-Tat 
To identify the composition of polymers that provides a gradual and persistent release of 
C3-Tat, the protein was encapsulated in various blends of capped and uncapped PLGA.  
The physical characteristics of C3-Tat microspheres were tabulated in Table 2 and 
scanning electron photomicrographs of representative microspheres from each 
formulation were shown in Fig. 13. All the formulations except 0/100 produced 
microspheres that are spherical in shape, with smooth and slightly porous surfaces (Fig. 
13 A-D). In contrast, the 0/100 microspheres showed rough surfaces and a greater level 
of surface porosity (Fig. 13 E). The internal microstructure of all the microspheres 
consisted of spherical pores (Fig. 13 F-J). The degree and distribution of internal porosity 
appears to be consistent regardless of microsphere formulation. Size of microspheres, 
however, was apparently independent of the polymer formulations. Mean diameter of the 
microspheres falls in the range of 74-85 µm. The encapsulation efficiency of the 










Table 2: Characteristics of microspheres. 
Microsphere formulation 
(Capped/uncapped PLGA) 
Microsphere size a 
(µm) 
Encapsulation 
efficiency b (%) 
100/0 83 ± 22 84.3 ± 0.5 
70/30 85 ± 26 80.4 ± 2.3 
50/50 76 ± 16 87.0 ± 1.3 
30/70 75 ± 16 84.8 ± 1.6 
0/100 74 ± 18 82.5 ± 2.0 
a Values are given as mean ± standard deviation of 100 representative microspheres 
   in each formulation 
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Fig. 13: SEM images of representative microspheres prepared from 100/0, 70/30, 50/50, 
30/70 and 0/100 capped/uncapped PLGA. A-E, surface morphology; F-J, internal 




























3.3.2. Protein release characteristics of C3-Tat microspheres 
It is known that PLGA microspheres degrade via a random chain scission of the ester 
linkages in the polymer backbone. The rate of degradation is critically dependent on the 
physicochemical properties of the polymer and greatly influences the release of the 
encapsulated drug. Hence, polymers with different functionalities at the end of the 
polymer chain were investigated in this study. PLGA (50:50) with a hydrophobic ester 
end-group (capped PLGA) is widely used for protein encapsulation studies, though an 
initial lag period during which very little or no protein release is usually observed [65, 
75]. This type of release characteristic clearly precludes a successful treatment regime. 
The blending of a PLGA possessing free carboxyl end-groups (uncapped PLGA) with the 
capped PLGA is expected to compensate for the lag period, ensuring protein release 
throughout the entire treatment period.   
 
To identify the optimal blending ratio which will provide the desired release profile, the 
release of C3-Tat from microspheres incubated in vitro in a HEPES buffer was 
































Fig. 14: Release of C3-Tat from microspheres prepared from blends of capped and 
uncapped PLGA. The proportions of capped PLGA/uncapped PLGA used to prepare the 
microspheres were: 100/0 (    ), 70/30 (    ), 50/50 (    ), 30/70 (    ) and 0/100 (    ). The 
microspheres were incubated at 37°C in a HEPES buffer, and the amount of C3-Tat 
released at each time point was determined by ELISA. The amount of C3-Tat released at 
each time point is expressed relative to the actual total amount of protein initially 
encapsulated in the microspheres. Error bars represent mean ± standard deviation for n=3. 
 
 
Microspheres containing 100% capped PLGA (100/0) exhibited less than 10% burst 
release within 24 hours, followed by a lag phase of about 19 days, during which almost 
no protein was released. Release gradually increased after this time and by day 28, only 
30% of encapsulated C3-Tat was released. In contrast, the release of C3-Tat from 
uncapped PLGA microspheres (sample 0/100) was characterized by an initial burst of 
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40% within the first 24 hours of incubation, followed by a subsequent average daily 
release rate of about 2.5% until a plateau value of about 80% encapsulated protein being 
released by day 28. The initial burst can be attributed to the immediate dissolution and 
release of the proteins near the surface of the microspheres [76]. It is likely that the rough 
surface feature of the 0/100 formulation confers a bigger surface area exposed to the 
aqueous environment, thereby increasing the rate and extent of initial hydration of the 
microspheres, leading to the large initial burst [76].   
 
The blends of various percentage of capped and uncapped PLGA exhibit intermediate 
release profiles between the two extremes, which is consistent with the observations 
published by other researchers [58, 59]. The initial lag period was gradually eliminated as 
the proportion of uncapped polymer in the microspheres was increased. Sample 70/30 
showed a lag of about 16 days while sample 50/50 had a lag period of 13 days. In 
particular, the lag period was completely eliminated in sample 30/70, which showed an 
initial burst of 25% and subsequently an average daily release rate of 2.3% (Fig.15).   
This translates to an average daily release of 3.0 ng/day/mg over a period of almost a 































Fig. 15: Non-cumulative release of C3-Tat from 30/70 capped/uncapped PLGA 
microspheres incubated at 37°C in a HEPES buffer. The amount of C3-Tat released at 
each time point is expressed relative to the actual total amount of protein initially 
encapsulated in the microspheres. Error bars represent mean ± standard deviation for n=3. 
 
 
3.3.3 Changes in physical characteristics of C3-Tat microspheres during 
degradation in vitro  
Release of protein drugs from microspheres occurs by diffusion through interconnected 
channels created by polymer degradation and erosion. The effect of addition of uncapped 
PLGA on the degradation and erosion characteristics of the microspheres, and hence the 
release of C3-Tat, was assessed by monitoring the molecular weight (Figs.16, 17), mass 
(Fig.18) and morphology (Fig.19) of the microspheres incubated in HEPES buffer. Other 
features of the microspheres and experimental conditions which could affect degradation 
rate were kept constant across the different blends. This allows the effect of endgroup 
chemistry on the degradation and erosion of microspheres to be studied. During 
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production of all of the microsphere blends, the double emulsion procedures and 
formulation parameters were kept constant. Therefore, the resulting microsphere sizes 
and level of internal porosity were consistently similar across the different blends.  
Similarly, the in vitro release conditions were kept constant for all the blends.  
 
Fig. 16 shows that sample 100/0 had an initial molecular weight of 32 kDa which 
decreased by less than 3% during the first 3 weeks. This slow rate of degradation 
(degradation rate constant of -0.0107 day-1, Table 3) explains the lack of significant mass 
loss (Fig.18) during the first 3 weeks. SEM images (Fig. 19a) also showed no 
morphological changes in the first three weeks. After this time, an increase in roughness 
and porosity at the surface of the microspheres was observed. The microspheres still 
retain their spherical shape. The lack of any significant degradation during the first three 
weeks of incubation accounts for the initial lag period during which very little C3-Tat 
was released. The increase in porosity after 3 weeks coincided with an increase in the rate 
of C3-Tat release. The overall triphasic (S-type) shape of the release profile is consistent 
with that typically seen for protein drugs encapsulated in capped PLGA [53, 54]. 
 
In contrast, the 0/100 microspheres exhibited different degradation characteristics. It has 
been shown that 15 kDa represents the critical value for PLGA at which oligomeric 
degradation products become water soluble, and hence the point at which erosion initiates 
[58]. Microspheres prepared from uncapped PLGA (sample 0/100) exhibited an initial 
molecular weight of 11 kDa which is already below the critical point.  It was observed 
that the molecular weight decreased by almost 30% within the first week of incubation 
  61
 
(Fig. 16). Together with the continuous loss of mass of the microspheres (Fig. 18) from 
the start of incubation, it is likely that PLGA degradation products are solubilised 
immediately, thereby facilitating microsphere erosion. This is supported by 
morphological analyses of microspheres, which show deformation and increased porosity 
within the first week of incubation (Fig. 19e). The microspheres became increasingly 
fragmented and porous with time.  The continuous erosion from the start of incubation 
coincided with the continuous release of C3-Tat upon immersion in the aqueous medium.   
 
When uncapped PLGA was blended with the capped polymer in varying proportions, the 
degradation kinetics of the resulting microspheres were altered. Increasing the proportion 
of uncapped polymer led to lower initial molecular weights, higher rates of degradation 
and mass loss as well as faster progression of pore formation and microsphere 
fragmentation. For all the blends, the point in time at which significant mass loss began 
coincided with an increased rate of release of C3-Tat. Cross section of the 30/70 
microspheres after 7 days of incubation (Fig. 20) showed the presence of newly formed 
internal pores on the walls of existing pores, hence leading to the formation of 
interconnected channels within the matrix. Formation of new pores was also observed in 
the 50/50 and 70/30 microspheres at a later time (after 14 days of incubation, data not 
shown). There is evidence that even in a homogenous mixture of two polymers, gelling 
and solidification of the polymers occurs separately [77]. In this case, it can be 
hypothesized that the more hydrated domains of the uncapped polymer within the 
microsphere matrix degrade and erode first, forming new pores and enlarging existing 
ones. These form interconnected channels through which polymer degradation products 
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and C3-Tat diffuse into the medium. The formation of such interconnected channels in 
the 30/70 microspheres early in the incubation period explains the sustained, constant 



























Fig. 16: Change in weight-average molecular weight of microspheres incubated at 37°C 
in HEPES buffer. The proportions of capped PLGA/uncapped PLGA used to prepare the 
microspheres were: 100/0 (   ), 70/30 (   ), 50/50 (   ), 30/70 (   ) and 0/100 (   ). Mw 






































Fig. 17: Semilog plots of normalized weight-average molecular weight versus time for 
the following samples: 100/0 (    ), 70/30 ( ), 50/50 (   ), 30/70 (   ) and 0/100 (    ). The 
weight-average molecular weight (Mw) at each time point was normalized to the initial 
weight-average molecular weight (Mwo). The line is a linear least-squares fit to the data.  
The degradation rate constant was determined from the slope of each line.  
 
 
Table 3: In vitro degradation kinetics of the microspheres. 




100/0 -0.0107 0.9597 
70/30 -0.0224 0.9847 
50/50 -0.0272 0.9734 
30/70 -0.0316 0.9108 
0/100 -0.0688 0.9583 




























Fig. 18: Mass loss profile of microspheres incubated at 37°C in HEPES buffer. The 
compositions of capped PLGA/uncapped PLGA used to prepare the microspheres were: 
100/0 ( ), 70/30 (   ), 50/50 (   ), 30/70 (   ) and 0/100 (   ).  Mass remaining at each time 
point was calculated by comparing the mass at a given time point to the initial mass. 










Fig. 19: SEM images of microspheres prepared from (a) 100/0, (b) 70/30, (c) 50/50, (d) 
30/70 and (e) 0/100 capped/uncapped PLGA, at various time points, after incubation in 



























Fig. 20: The internal pore structure of 30/70 microspheres after 7 days of incubation in 




3.3.4. Bioactivity of released C3-Tat 
The activity of C3-Tat released from PLGA microspheres over time was examined by 
measuring its catalysis of ADP-ribosylation of recombinant RhoA with an in vitro assay. 
By interpolation of the standard curve (Fig. 6), the amount of active C3-Tat present in 
each sample at each time point was determined, and expressed as a percentage of the total 
C3-Tat released (as detected by ELISA) (Fig. 21). The biological activity of C3-Tat was 
maintained in the 30/70 microspheres for at least 19 days, as at least 40% of the released 
C3-Tat during this period was found to be active. After 19 days, the activity of C3-Tat 












































Fig 21:  Percentage of C3-Tat that remains active after being released from the 30/70 
microspheres. The amount of active C3-Tat in each release sample at every time point 
was determined by an in vitro assay in which C3-Tat was incubated with recombinant 
RhoA and β-NAD in a suitable buffer. ADP-ribosylation of RhoA was detected as an 
increase in molecular weight of RhoA on a Western blot. The amount of active C3-Tat at 
each time point is expressed as a percentage of the total C3-Tat released at that time point 













In this study, the approach of blending polymers with hydrophobic ester end-groups 
(capped PLGA) and hydrophilic carboxyl end-groups (uncapped PLGA) for controlling 
the release rate of encapsulated C3 was investigated. As the molecular weight of blends 
was found to be different, the observed differences in degradation rate and therefore 
release rate of the blends cannot be attributed entirely to the addition of uncapped PLGA. 
However, a study comparing microspheres prepared from 12 kDa capped and uncapped 
50:50 PLGA respectively reported slower release of protein from the capped PLGA 
microspheres [78]. It was proposed that the higher hydrophilicity of the uncapped PLGA 
gave rise to a faster degradation rate. Indeed, other studies have found that PLGA 
molecular weight had a much smaller effect than the end group on the degradation rate 
constant of microspheres [69].  In the same study [69] it was found that uncapped PLGA 
degraded faster because of the catalysis of ester bond hydrolysis due to the larger number 
of free carboxyl end groups, and also because of larger rate of water uptake. Therefore, 
the increase in degradation rate and release rate observed in our study when the 
proportion of uncapped PLGA is increased is likely to be due mainly to the effect of the 
free carboxylic endgroups, rather than the drop in molecular weight. 
 
For every blend, an increased rate of release of C3-Tat was consistently observed at the 
point in time when physical erosion of the microspheres occurred. This is an indication 
that the release of protein from the microspheres in this study is erosion-controlled. The 
optimal blending ratio which resulted in continuous release immediately upon immersion 
in a buffer solution was found to be 30/70 ratio of capped/uncapped PLGA. After an 
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initial burst of 25%, an average daily protein release of 3.0 ng/day/mg microspheres was 
observed. The initial burst could be advantageous in this application, as there is evidence 
that the application of a large dose of C3 to injured CNS tissue within the first 24 hours 
after injury leads to increased neuroprotection [16]. Neuronal survival in the early stages 
of injury is important for successful functional recovery. After the burst, maintenance of 
C3 release at a constant level would ensure continual supply of the protein necessary for 
long-distance axonal regeneration of the injured neurons. 
 
Proteins are known to be susceptible to denaturation, aggregation and adsorption at 
interfaces, all of which affects their conformation in solution, and in turn their biological 
activity. It is known that when microspheres encapsulating proteins are prepared by the 
w/o/w double emulsion method, the protein is especially susceptible to adsorption and 
denaturation at the water/organic solvent interface [78, 79]. The other major factor 
contributing to instability of the encapsulated protein is the in vitro release conditions 
[80, 81]. As such, the activity of C3-Tat released from the incubated microspheres at 
various time points was also studied. 
 
The C3-Tat released on the first day provides an indication of the effect of the 
microencapsulation processing steps on the integrity of the protein, as the protein would 
not have been exposed to the medium for extended periods of time. This study has shown 
that 70% of the released C3-Tat on the first day of incubation is still biologically active. 
This value indicates that the method of stabilization of C3 (i.e. addition of PEG to the 
inner aqueous phase) during the encapsulation procedure can be further optimized. It is 
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likely that PEG was not completely effective in protecting C3. It is speculated that it is 
most likely the primary emulsification step which poses the most harm to C3. The use of 
other excipients reported to prevent emulsification-induced denaturation and degradation 
of proteins should be investigated. Such excipients include osmolytes, such as trehalose 
and mannitol, which acts by shielding proteins from the organic solvent by preferential 
hydration [78]. In addition, the type of organic solvent can also influence protein 
stability. Compared to the more hydrophobic dichloromethane, ethyl acetate has been 
reported to induce less denaturation of proteins [82]. 
 
The observed steady drop in activity of C3-Tat over the subsequent days is similar to that 
reported by other researchers in similar studies where microspheres were suspended in a 
fixed volume of buffer in a closed container [80, 83]. The loss of protein integrity during 
incubation of microspheres in vitro has been attributed to protein aggregation following 
initial rehydration of the microspheres, to protein adsorption to the polymer, or to the 
acidification of the release medium by PLGA degradation products [81, 84]. In this study, 
the use of HEPES buffer (which has larger buffer capacity than phosphate-buffered 
saline, PBS) and replacement of buffer every 3 days, led to maintenance of release 
medium at pH 7 throughout the study period (data not shown). Although the pH 
measured was of the buffer outside of the microspheres, it is speculated that the internal 
environment within the microspheres will not be very different, as the high porosity of 
the microspheres allows for rapid diffusion of degradation products into the surrounding 
medium. As such, the soluble degradation products of PLGA consisting of monomers and 
oligomers may be compromising the stability of C3-Tat in other ways. For example, the 
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degradation products may exert co-solvent effects on C3-Tat, i.e. their presence may 
decrease conformational stability [80]. Prolonged exposure of C3-Tat in solution at 37°C 
may also contribute to its instability [81].  
 
After 19 days of incubation, the amount of active C3-Tat in the medium drops drastically, 
though the protein is still detectable by ELISA. This is an indication that after a long 
period of incubation, C3-Tat still maintains its immunoreactivity (i.e. its recognition by 
antibodies) but loses much of its biological activity. There is evidence from previous 
studies [84 – 87] that antigen reactivity may not be strictly related to biological activity 
because a protein may lose biological activity without losing its epitopes reactivity. The 
drastic drop in activity after about 19 days of incubation may be explained by the 
increasing porosity and hydration of microspheres with time, which expose C3-Tat in 
microspheres to the environmental stresses described above.  
 
The in vitro release study conditions are not representative of the actual in vivo situation, 
where the polymer degradation products may be readily cleared away [67]. It is not 
possible to mimic exactly the in vivo environmental conditions in an in vitro setup. 
Despite the limitations of in vitro studies, they are still useful as a screening tool during 
optimization of microsphere formulations. As such, it is worthwhile optimizing the in 
vitro conditions. Variables in the release medium which can be optimized include pH, 
buffer species, ionic strength and salt concentration. There is evidence that the buffer 
components in the release medium make a big difference in retaining protein activity 
during prolonged incubation at 37°C [ref 80, 81].  
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It should be noted that while in vitro studies provide a simple preliminary method to 
identify microsphere formulations which give the desired release profile and protein 
stability, such studies may not accurately assess the biological efficacy of the 
microspheres. Further in vivo studies in rodent models are necessary to assess and 

























CONCLUSIONS AND RECOMMENDATIONS 
 
4.1. Conclusions 
The objective of this study was to assess the feasibility of encapsulating recombinant C3-
Tat protein within PLGA microspheres to achieve a gradual and localized release of 
active protein over an extended period of time. The degradation rate of the microspheres 
can be controlled by the blending ratio of capped and uncapped PLGA. The release of 
C3-Tat from the microspheres was controlled by matrix erosion, where interconnected 
channels facilitated diffusion of the protein from the matrix.  It was demonstrated that the 
optimal blending ratio giving rise to microspheres fulfilling the requirement of 
continuous release for at least one month, was a 30/70 ratio of capped/uncapped PLGA.  
In this formulation, an average daily C3-Tat release of 3.0 ng/day/mg microspheres was 
observed for a period of one month.  
 
While this study has demonstrated that the release characteristics of the microspheres are 
suitable for our target application, the activity levels of released C3-Tat could not be 
accurately assessed, given the instability of the protein in the in vitro release conditions. 
70% of the released C3-Tat on the first day of incubation was found to be active. At least 
40% of C3-Tat biological activity was maintained in the 30/70 microspheres for 19 days. 
After 19 days, the activity of C3-Tat dropped to very low levels. These results indicate 
that the method of stabilization of C3 during the encapsulation procedure and release 
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studies can be further optimized. Further characterization of the C3-Tat microspheres in 




4.2. Recommendations for future work 
A comprehensive formulation study for C3-Tat should be conducted, where different 
stabilization methods are systematically tested to identify one that will ensure that C3 
retains its activity during the emulsification process and during in vitro incubation.  
 
To ensure that microspheres remain localized at the required site in the spinal cord, it is 
proposed that the C3-Tat microspheres be suspended in a gel matrix, e.g. collagen or 
fibrin matrix. In this way the axonal growth supporting properties of these gels can also 
be exploited. The release characteristics of C3-Tat may be altered due to the presence of 













[1] C.E. Hulsebosch, Recent advances in pathophysiology and treatment of spinal 
cord injury, Adv. Physiol. Educ. 26 (2002) 238-255. 
[2] J.W. Mcdonald, C. Sadowsky, Spinal cord injury seminar, Lancet 359 (2002) 
417-425. 
[3] R.J. McKeon, R.c. Schreiber, J.S. Rudge, J. Silver, Reduction of neurite 
outgrowth in a model of glial scarring following CNS injury is correlated with the 
expression of inhibitory molecules on reactive astrocytes, J. Neurosci. 11 (1991) 
3398-3411. 
[4] R.A. Asher, D.A. Morgenstern, P.S. Fidler, K.H. Adcock, A. Oohira, J.E. 
Braistead, J.M. Levine, R.U. Margolis, J.H. Rogers, J.W.Fawcett, Neurocan is 
upregulated in injured brain and in cytokine-treated astrocytes, J. Neurosci. 20 
(2000) 2427-2438. 
[5] R.J. Pasterkamp, F. De Winter, R.J. Giger, J. Verhaagen, Role for semaphorin III 
and its receptor neuropilin-1 in neuronal regeneration and scar formation? Prog. 
Brain Res. 117 (1998) 151-170.  
[6] M.E. Schwab, P. Caroni, Rat CNS myelin and a subtype of oligodendrocytes in 
culture represent a non-permissive substrate for neurite growth and fibroblast 
spreading, J. Neurosci. 8 (1988) 2381-2393. 
[7] R. Prinjha, S.E. Moore, M. Vinson, S. Blake, R. Morrow, G. Christie, et al., 
Inhibitor of neurite outgrowth in humans, Nature 403(2000) 383-384. 
  78
 
[8] K.C. Wang, V. Koprivica, J.A. Kim, R. Sivasankaran, Y. Guo, R.L. Neve, Z. He, 
Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits 
neurite outgrowth, Nature 417 (2002) 941-944. 
[9] L. McKerracher, S. David, D.L. Jackson, V. Kottis, R.J. Dunn, P.E. Braun, 
Identification of myelin-associated glycoprotein as a major myelin-derived 
inhibitor of neurite outgrowth, Neuron 13 (1994) 805-811. 
[10] A. Sandvig, M. Berry, L.B. Barrett, A. Butt, A. Logan, Myelin-, reactive glia-, 
and scar-derived CNS axon growth inhibitors: Expression, receptor signaling and 
correlation with axon regeneration, Glia 46 (2004) 225-251. 
[11] B.J. Dickson, Rho GTPases in growth cone guidance, Curr. Opin. Neurobiol. 11 
(2001) 103-110. 
[12] L. Luo, Rho GTPases in neuronal morphogenesis, Nature Rev. Neurosci. 1 (2000) 
173-180. 
[13] M. Lehmann, A. Fournier, I.Selles-Navarro, P. Dergham, A. Sebok, N. Leclerc, et 
al., Inactivation of Rho signaling pathway promotes CNS axon regeneration, J. 
Neurosci. 19 (1999) 7537-7547. 
[14] A.E. Fournier, B.T. Takizawa, S.M. Strittmatter, Rho kinase inhibition enhances 
axonal regeneration in the injured CNS, J. Neurosci. 23 (2003) 1416-1423. 
[15] Z. Jin, S.M. Strittmatter, Rac1 mediates collapsing-1 induced growth cone 
collapse. J. Neurosci. 17 (1997) 6256-6263. 
[16] P. Dergham, B. Ellezam, C. Essagian, H. Avedissian, W.D. Lubell, L. 
Mckerracher, Rho signaling pathway targeted to promote spinal cord repair, J. 
Neurosci. 22 (2002) 6570-6577. 
  79
 
[17] U. Laufs, M. Endres, N. Stagliano, S. Amin-Hanjani, D.S, Chui, et al., 
Neuroprotection mediated by changes in the endothelial actin cytoskeleton, J. 
Clin. Invest. 106 (2000) 15-24. 
[18] T. Trapp, L. Olah, I. Holker, M. Besselmann, C. Tiesler, K. Maeda, K.A. 
Hossmann, GTPase RhoB: an early predictor of neuronal death after transient 
focal ischemia in mice, Mol. Cell. Neurosci. 17 (2001) 883-894. 
[19] R.J. Ridley, A. Hall, The small GTP-binding protein Rho regulates the assembly 
of focal adhesions and stress fibres in response to growth factors,  Cell 70 (1992) 
389-399 
[20] E.J. Rubin, M.D. Gill, P.Boquet, M.R. Popoff, Functional modification of a 21-
kilodalton G Protein when ADP-ribosylated by exoenzyme C3 of Clostridium 
botulinum, Mol. Cell. Biol. 8 (1988) 418. 
[21] Y. Saito, S. Narumiya, Preparation of Clostridium botulinum C3 exoenzyme and 
application of ADP-ribosylation of Rho proteins in biological systems, in: K. 
Aktories (Ed.), Bacterial toxins, Chapman&Hall, Weinhem, 1997, pp 85-92. 
[22] M. Green, P.M. Loewenstein, Autonomous functional domains of chemically 
synthesized human immunodeficiency virus tat trans-activator protein, Cell 55 
(1988) 1179-1188. 
[23] A.D. Frankel, C.O. Pabo, Cellular uptake of the tat protein from human 
immunodeficiency virus, Cell 55 (1988) 1189-1193. 
[24] S.K. Arya, C. Guo, S.F. Josephs, F. Wong-Staal, Transactivator gene of human T-
lymphotropic virus type III, Science 229 (1985) 69-75. 
[25] E. Vives, P. Brodin, B. Leblus, A truncated tat basic domain rapidly translocates 
  80
 
through the plasma membrane and accumulates in the nucleus, J. Biol. Chem. 272 
(1997) 16010-16017. 
[26] S.R. Schwarze, A. Ho, A. vocero-Akbani, S.F. Dowdy, In vivo protein 
transduction: delivery of a biologically active protein into the mouse, Science 285 
(1999) 1569-1572 
[27] M. J. Winton, C.I. Dubreuil, D. Lasko, N. Leclerc, L. McKerracher, 
Characterization of new cell permeable C3-like proteins that inactivate Rho and 
stimulate neurite outgrowth on inhibitory substrates, J. Biol. Chem. 277 (2002) 
32820-32829. 
[28] P.A. Dijkhuizen, J.Verhaagen, The use of neurotrophic factors to treat spinal cord 
injury: advantages and disadvantages of different delivery methods, Neurosci. 
Res. Commun. 24 (1999) 1-10. 
[29] Medtronic, Introduction to intrathecal drug delivery. Available at: 
http://www.medtronic.com/neuro/paintherapies/pain_treatment_ladder/drug_infus
ion/drug_drug_deliv.html, Accessed on 27 March 2005. 
[30] T. GrandPre, S. Li, S.M. Strittmattter, Nogo-66 receptor antagonist peptide 
promotes axonal regeneration, Nature 417 (2002) 547-551. 
[31] M.S. Ramer, J.V. Priestley, S.B. McMahon, Functional regeneration of sensory 
axons into the adult spinal cord, Nature 403 (2000) 312-316. 
[32] L.L. Jones, M.H. Tuszynski, Chronic intrathecal infusions after spinal cord injury 
cause scarring and compression, Microsc. Res. Tech. 54 (2001) 317-324. 
  81
 
[33] R.D. Penn, J.S. Kroin, M.M. York, Intrathecal ciliary neurotrophic factor delivery 
for treatment of amyotrophic lateral sclerosis (phase I trial), Neurosurgery 40 
(1997) 94-99. 
[34] S.J. Taylor, J.W. Mcdonald III, S.E. Sakiyama-Elbert, Controlled release of 
neurotrophin-3 from fibrin gels for spinal cord injury, J Control. Release 98 
(2004) 281-294. 
[35] L.L. Jones, R.U. Margolis, M.H. Tuszynski, The chondroitin sulfate 
proteoglycans neurocan, brevican, phosphacan, and versican are differentially 
regulated following spinal cord injury, Exp. Neurol. 182 (2003) 399–411. 
[36] A. Buss, K. Pech, D. Merkler, B.A. Kakulas, D. Martin, J. Schoenen, J. Noth, 
M.E Schwab, G.A. Brook, Sequential loss of myelin proteins during Wallerian 
degeneration in the human spinal cord, Brain 128 (2005) 356-364. 
[37] A.H. Zisch, M.P. Lutolf, J.A. Hubbell, Biopolymeric delivery matrices for 
angiogenic growth factors, Cardiovasc. Pathol. 12 (2003) 295–310. 
[38] P.K. Shireman, B. Hampton, W.H. Burgess, H.P. Greisler, Modulation of vascular 
cell growth kinetics by local cytokine delivery from fibrin glue suspensions, J. 
Vasc. Surg. 29 (1999) 852-861. 
[39] D.G. Wallacea, J. Rosenblattb, Collagen gel systems for sustained delivery and 
tissue engineering, Adv. Drug. Deliv. Rev. 55 (2003) 1631– 1649. 
[40] S. Li, M. Vert, Biodegradable polymers: Polyesters in: E. Mathiowitz, 




[41] V.R. Sinha, A. Trehan, Biodegradable microspheres for protein delivery, J. 
Control. Release 90 (2003) 261-280. 
[42] P.A. Lee, Treatment of central precocious puberty with depot lupron, in: G.D. 
Grave, Sexual precocity: etiology, diagnosis and management, Raven Press, New 
York, 1993, pp 139-150. 
[43] R.A. Jain, The manufacturing techniques of various drug loaded biodegradable 
poly(lactide-co-glycolide) (PLGA) devices, Biomaterials 21 (2000) 2475-2490. 
[44] O.L. Johnson, M.A. Tracy, Peptide and protein drug delivery, in: E. Mathiowitz, 
Encyclopedia of controlled drug delivery, Wiley-Interscience, New York, 1999, 
pp 816-833. 
[45] X. Li, X. Deng, Z. Huang, In vitro protein release and degradation of poly-dl-
lactide-poly(ethylene glycol) microspheres with entrapped human serum albumin: 
quantitative evaluation of the factors involved in protein release phases, Pharm. 
Res. 18 (2001) 117-124. 
[46] R.C. Mehta, J. Ramasbu, S. Calis, B.C. Thanoo, K. W. Burton, P.P. DeLuca, 
Biodegradable microspheres as depot system for parenteral delivery of peptide 
drugs, J. Control. Release 29 (1994) 375-384. 
[47] D.T. O’Hagan, J.P. McGee, R. Boyle, D. Gumaer, X-M. Li, B. Potts, C.Y. Wang, 
W.C. Koff, The preparation, characterization and pre-clinical evaluation of an 
orally administered HIV-1 vaccine, consisting of a branched peptide immunogen 




[48] D.Bodmer, T. Kissel, E. Traechslin, Factors influencing the release of peptides 
and proteins from biodegradable parenteral depot systems, J. Control. Release 21 
(1992) 129-138. 
[49] T.G. Park, Degradation of poly(dl-lactic acid) microspheres: effect of molecular 
weight, J. Control. Release, 30 (1994) 161-173. 
[50] G. Crotts, T.G. Park, Preparation of porous and nonporous biodegradable 
polymeric hollow microspheres, J. Control. Release 35 (1995) 91-105. 
[51] M. Sandor, D. Enscore, P. Weston, E. Mathiowitz, Effect of protein molecular 
weight on release from micron-sized PLGA microspheres, J Control. Release 76 
(2001) 297-311. 
[52] D.T. O’Hagan, H. Jeffery, S.S. Davis, The preparation and characterization of 
poly(lactide-co-glycolide) microparticles:III. Microparticle/polymer degradation 
rates and the in vitro release of a model protein, Int. J. Pharm. 103 (1994) 37-45. 
[53] C. Sturesson, J. Carlfors, Incorporation of protein in PLG-microspheres with 
retention of bioactivity, J Control. Release 67 (2000) 171-178. 
[54] J-M. Pean, M-C. Venier-Julienne, F. Boury, P. Menei, B. Denizot, J-P. Benoit, 
NGF release from poly(D,L-lactide-co-glycolide) microspheres. Effect of some 
formulation parameters on encapsulated NGF stability, J Control. Release 56 
(1998) 175-187. 
[55] W. Jiang and S.P. Schwendeman, Stabilization and controlled release of bovine 
serum albumin encapsulated in poly(D,L-lactide) and poly(ethylene glycol) 
microsphere blends, Pharm. Res. 18 (2001) 878-885. 
  84
 
[56] H.K. Kim, T.G. Park, Comparative study on sustained release of human growth 
hormone from semi-crystalline poly(L-lactic acid) and amorphous poly(D,L-
lactic-co-glycolic acid) microspheres: morphological effect on protein release, J. 
Control. Release 98 (2004) 115-125. 
[57] H.K. Sah, R. Toddywala and Y.W. Chien, The influence of biodegradable 
microcapsule formulations on the controlled release of a protein, J. Control. 
Release 30 (1994) 201-211. 
[58] W. Friess and M. Schlapp, Modifiying the release of gentamicin from 
microparticles using a PLGA blend, Pharm. Dev. Technol. 7 (2002) 235-248. 
[59] H.B. Ravivarapu, K. Burton, P.P. Deluca, Polymer and microsphere blending to 
alter the release of a peptide from PLGA microspheres, Eur. J. of Pharm. 
Biopharm. 50 (2000) 263-270. 
[60] W. Wang, Instability, stabilization, and formulation of liquid protein 
pharmaceuticals, Int. J. Pharm. 185 (1999) 129-188.  
[61] M. van de Weert, W.E. Hennink, W. Jiskoot, Protein instability in poly(lactic-co-
glycolic acid) microparticles, Pharm. Res. 17 (2000) 1159-1165. 
[62] R. Krishnamurthy, J.A. Lumpkin and R. Sridlar, Inactivation of lysozyme by 
sonication under conditions relevant to microencapsulation, Int. J. Pharm. 205 
(2000) 23-34. 
[63] H. Sah, Protein behaviour at the water/methylene chloride interface, J. Pharm. 
Sci. 88 (1999) 1320-1325. 
  85
 
[64] C.P. Rodriguez, N. Montano, K. Gonzalez, K. Griebenow, Stabilization of α-
chymotrypsin at the CH2Cl2 / water interface and upon water-in-oil-in-water 
encapsulation in PLGA microspheres, J. Control. Release 89 (2003) 71-85. 
[65] J.M. Pean, F. Boury, M.C. Vernier-Julienne, P. Menei, J.E. Proust, J.P. Benoit, 
Why does PEG 400 Co-encapsulation improve NGF stability and release from 
PLGA biodegradable microspheres? Pharm. Res. 16 (1999) 1294-1299. 
[66] T. Uchida, K. Shiosaki, Y. Nakada, K. Fukada, Y. Eda, S. Tokiyoshi, N. 
Nagareya and K. Matsuyama, Microencapsulation of hepatitis B core antigen for 
vaccine preparation, Pharm. Res. 15 (1998) 1708-1713. 
[67] T.G. Park, W. Lu, G. Crotts, Importance of in vitro experimental conditions on 
protein release kinetics, stability and polymer degradation in protein encapsulated 
poly(D,L-lactic acid-co-glycolic acid) microspheres, J Control. Release 33 (1995) 
211-222. 
[68] G. Zhu, S.R. Mallery, S.P. Schwenderman, Stabilization of proteins encapsulated 
in injectable poly(lactide-co-glycolide), Nature Biotech. 18 (2000) 52-57. 
[69] M.A. Tracy, K.L. Ward, L. Firouzabadian, Y. Wang, N. Dong, R. Qian, Y. 
Zhang, Factors affecting the degradation rate of poly(lactide-co-glycolide) in vivo 
and in vitro, Biomaterials 20 (1999) 1057-1062. 
[70] C. Yan, J.J. Resau, J. Heweston, M. West, W.L. Rill, M. Kende, Characterization 
and morphological analysis of protein-loaded poly(lactide-co-glycolide) 
microparticles prepared by water-in-oil-in-water emulsion technique, J Control. 
Release 32 (1994) 231-241. 
[71] P.K. Smith, R.I. Krohn, G.T. Hermanson, A.K. Mallia, F.H. Gartner, M.D. 
  86
 
Provenzano, et al, Measurement of protein using bicinchroninic acid, Anal. 
Biochem. 150 (1985) 76-85. 
[72] E.P. Magre and A.P. Sam, Hydrolytic degradation of PLAGA, calculation of rate 
constants from various types of in vitro degradation curves, J Control. Release 48 
(1997) 318-319. 
[73] S.T. Dillon and L.A. Feig, Purification and assay of recombinant C3 transferase, 
Methods Enzymol. 256 (1995) 174-184. 
[74] M. Narito, S. Narumiya, Preparation of native and recombinant Clostridium 
botulinum C3 ADP-ribosyltransferase and identification of Rho proteins by ADP-
ribosylation, Methods Enzymol. 256 (1995) 96-206. 
[75] X.M. Lam, E.T. Duenas, A.L. Daugherty, N. Levin, J.L. Cleland, Sustained 
release of recombinant human insulin-like growth factor-I for treatment of 
diabetes, J. Control. Release 67 (2000) 281-292. 
[76] C.G. Pitt, M.M Gratzl, G.L. Kimmel, J. Surles and A. Schindler, Aliphatic 
polyesters II. The degradation of poly(DL-lactide), poly(epsilon-caprolactone) 
and their copolymers in vivo, Biomaterials 2 (1981) 215-220. 
[77] W.I. Li, K.W. Anderson, P.P. Deluca, Prediction of solvent removal profile and 
effect on properties for peptide-loaded PLGA microspheres prepared by solvent 
extraction/evaporation method, J. Control. Release 37 (1995) 199-214. 
[78] J.L. Cleland, A.J.S. Jones, Stable formulations of recombinant human growth 
hormone and interferon-γ for microencapsulation in biodegradable microspheres, 
Pharm. Res. 13 (1996) 1464-1475. 
  87
 
[79] M. Wolf, M. Wirth, F. Pittner, F. Gabor, Stabilization and determination of the 
biological activity of L-asparaginase in poly(D,L-lactide-co-glycolide) 
nanospheres, Int. J. Pharm. 256 (2003) 141-152. 
[80] A.A. Pouessel, M.C. Vernier-Julienne, A. Claveul, M. Sergent, C. Jollivet, N. 
C.N. Montero-Menei, et al., In vitro study of GDNF release from biodegradable 
PLGA microspheres, J. Control. Release 95 (2004) 463-475. 
[81] J. Yang, J.L. Cleland, Factors affecting the in vitro release of recombinant human 
interferon-γ (rhIFN-γ) from PLGA microspheres, J. Pharm. Sc. 86 (1997) 908-
914. 
[82] H. Sah, Protein instability toward organic solvent/water emulsification: 
Implications for protein microencapsulation into microspheres, PDA J. Pharm. 
Sci. Technol. 53 (1999) 3-10. 
[83] I.J. Castellanos, R. Crespo, K. Griebenow, Poly(ethylene glycol) as stabilizer and 
emulsifying agent: a novel stabilization approach preventing aggregation and 
inactivation of proteins upon encapsulation in bioerodible polyester microspheres, 
J. Control. Release 88 (2003) 135-145. 
[84] S.P. Schwendeman, M. Cardamone, M.R. Brandon, A. Kilbanov, R. Langer, 
Stability of proteins and their delivery from biodegradable polymer microspheres, 
in S.Cohen, H. Bernstein (Eds.), Microparticulate systems for the delivery of 
proteins and vaccines, Marcel Dekker, New York, 1996. 
[85] S.C. Piscitelli, W.G. Reiss, W.D. Figg, W.P. Petros, Pharmacokinetic studies with 
recombinant cytokines, scientific issues and practical considerations, Clin. 
Pharmacokinet. 32 (1997) 368-381. 
  88
 
[86] A. Sanchez, M. Tobio, L. Gonzalez, A. Fabra, M.J. Alonso, Biodegradable micro- 
and nanoparticles as long-term delivery vehicles for interferon-alpha, Eur. J. of 
Pharm. Sc. 18 (2003) 221-229. 
[87] L. Chen, R.N. Apte, S. Cohen, Characterization of PLGA microspheres for the 
controlled delivery of IL-1α for tumor immunotherapy, J. Control. Release 43 
(1997) 261-272. 
 
 
